Patented Medicines For Human Use Reported to the PMPRB in 2020*
January 1 to December 31, 2020
A
Abbvie Corporation
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02474263 | HUMIRA - 20 MG/SYRINGE | adalimumab | L04AB | Parenteral/Solution | Introduced | Within Guidelines |
| 02258595 | HUMIRA - 40 MG/SYRINGE | adalimumab | L04AA | Parenteral/Solution | blank | Within Guidelines |
| 02243644 | KALETRA 80/20 MG/MILLILITER | lopinavir/ritonavir | J05AE | Oral Liquid/Solution | blank | Within Guidelines |
| 02312301 | KALETRA 100/25 MG/TABLET | lopinavir/ritonavir | J05AE | Oral Solid/Tablet | blank | Does Not Trigger |
| 02285533 | KALETRA 200/50 MG/TABLET | lopinavir/ritonavir | J05AE | Oral Solid/Tablet | blank | Within Guidelines |
| 02467550 | MAVIRET 100/40 MG/TABLET | glecaprevir/pibrentasvir | J05AP | Oral Solid/Tablet | blank | Subj. Investigation |
| 02357593 | NORVIR - 100 MG/TABLET | ritonavir | J05AE | Oral Solid/Tablet | blank | Within Guidelines |
| 02481332 | ORILISSA - 150 MG/TABLET | elagolix | G03XA | Oral Solid/Tablet | blank | Within Guidelines |
| 02481340 | ORILISSA - 200 MG/TABLET | elagolix | G03XA | Oral Solid/Tablet | blank | Within Guidelines |
| 02495155 | RINVOQ - 15 MG/TABLET | upadacitinib | L04AA | Oral Solid/Modified release tablets | Introduced | Does Not Trigger |
| 02487454 | SKYRIZI - 75 MG/SYRINGE | risankizumab | L04AC | Parenteral/Solution | blank | Within Guidelines |
| 02438372 | SYNAGIS - 50 MG/VIAL | palivizumab | J06BB | Parenteral/Solution | blank | Within Guidelines |
| 02438364 | SYNAGIS - 100 MG/VIAL | palivizumab | J06BB | Parenteral/Solution | blank | Within Guidelines |
| 02458039 | VENCLEXTA - 10 MG/TABLET | venetoclax | L01XX | Oral Solid/Tablet | blank | Within Guidelines |
| 02458047 | VENCLEXTA - 50 MG/TABLET | venetoclax | L01XX | Oral Solid/Tablet | blank | Within Guidelines |
| 02458055 | VENCLEXTA - 100 MG/TABLET | venetoclax | L01XX | Oral Solid/Tablet | blank | Within Guidelines |
| 02458063 | VENCLEXTA 10/50/100 | venetoclax | L01XX | Oral Solid/Tablet | blank | Within Guidelines |
Advanced Accelerator Applications
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02490005 | NETSPOT - 40 MCG/VIAL | oxodotreotide | V09I | Parenteral/Solution | Introduced | Within Guidelines |
Aerie Pharmaceuticals, Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| blank | RHOPRESSA - 0.2 MG/MILLILITER | netarsudil | S01EX | Ophthalmic/Solution | blank | Within Guidelines |
Akcea Therapeutics Canada
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02481383 | TEGSEDI - 284 MG/SYRINGE | inotersen | N07XX | Parenteral/Solution | blank | VCU |
Alexion Pharmaceuticals Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02469596 | KANUMA - 2 MG/MILLILITER | sebelipase alfa | A16AB | Parenteral/Solution | blank | Within Guidelines |
| 02322285 | SOLIRIS - 10 MG/MILLILITER | eculizumab | L04AA | Parenteral/Solution | blank | Subject to Stay Order |
| 02444615 | STRENSIQ - 18 MG/VIAL | asfotase alfa | A16AB | Parenteral/Solution | blank | Within Guidelines |
| 02444623 | STRENSIQ - 28 MG/VIAL | asfotase alfa | A16AB | Parenteral/Solution | blank | Within Guidelines |
| 02444631 | STRENSIQ - 40 MG/VIAL | asfotase alfa | A16AB | Parenteral/Solution | blank | Within Guidelines |
| 02444658 | STRENSIQ - 80 MG/VIAL | asfotase alfa | A16AB | Parenteral/Solution | blank | Within Guidelines |
Alk-Abello A S
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02418304 | GRASTEK - 2800 UNIT/TABLET | standardized allergen extract, timothy grass (phleum pratense) | V01AA | Dental - Sublingual Buccal/Sublingual tablets | blank | Within Guidelines |
| 02498073 | ITULATEK - 12 UNIT/TABLET | standardized allergen extract, white birch (betula verrucosa) | V01AA | Oral Solid/Tablet | Introduced | Within Guidelines |
| 02423723 | RAGWITEK - 12 UNIT/TABLET | standardized short ragweed pollen allerganic extract | V01AA | Dental - Sublingual Buccal/Sublingual tablets | blank | Within Guidelines |
Alkermes Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| blank | VIVITROL - 380 MG/VIAL | naltrexone | N07BB | Parenteral/Suspension (extended release) | blank | Subj. Investigation |
Allergan Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02242518 | ACTONEL - 5 MG/TABLET | risedronate sodium | M05BA | Oral Solid/Tablet | blank | Within Guidelines |
| 02246896 | ACTONEL - 35 MG/TABLET | risedronate sodium | M05BA | Oral Solid/Tablet | blank | Within Guidelines |
| 02316838 | ACTONEL - 150 MG/TABLET | risedronate sodium | M05BA | Oral Solid/Tablet | blank | Does Not Trigger |
| 02370417 | ACTONEL DR - 35 MG/TABLET | risedronate sodium | M05BA | Oral Solid/Modified release tablets | blank | Within Guidelines |
| 01968300 | ACULAR - 5 MG/MILLILITER | ketorolac tromethamine | S01BC | Ophthalmic/Liquid | blank | Within Guidelines |
| 02248722 | ACULAR LS - 4 MG/MILLILITER | ketorolac tromethamine | S01BC | Ophthalmic/Liquid | blank | Does Not Trigger |
| 02369362 | ACUVAIL - 4.5 MG/MILLILITER | ketorolac tromethamine | S01BC | Ophthalmic/Drops | blank | Within Guidelines |
| 02236876 | ALPHAGAN - 2 MG/MILLILITER | brimonidine tartrate | S01EA | Ophthalmic/Drops | blank | Within Guidelines |
| 02248151 | ALPHAGAN P - 1.5 MG/MILLILITER | brimonidine tartrate | S01EA | Ophthalmic/Liquid | blank | Within Guidelines |
| 02239653 | ANDRODERM - 12.2 MG/PATCH | testosterone | G03BA | Topical/Patches | blank | Does Not Trigger |
| 02245972 | ANDRODERM - 24.3 MG/PATCH | testosterone | G03BA | Topical/Patches | blank | Within Guidelines |
| 01997580 | ASACOL 400 - 400 MG/TABLET | mesalazine | A07EC | Oral Solid/Modified release tablets | blank | Within Guidelines |
| 02267217 | ASACOL 800 - 800 MG/TABLET | mesalazine | A07EC | Oral Solid/Modified release tablets | blank | Within Guidelines |
| 02443910 | BELKYRA - 10 MG/MILLILITER | deoxycholic acid | D11AX | Parenteral/Solution | blank | Within Guidelines |
| 01981501 | BOTOX - 100 UNIT/VIAL | onabotulinumtoxina | M03AX | Parenteral/Powder for solution | blank | Within Guidelines |
| 02243721 | BOTOX COSMETIC - 100 UNIT/VIAL | onabotulinumtoxina | M03AX | Parenteral/Powder for solution | blank | Within Guidelines |
| 02248347 | COMBIGAN 2/5 MG/MILLILITER | brimonidine tartrate/timolol maleate | S01ED | Ophthalmic/Drops | blank | Within Guidelines |
| 02469510 | CONSTELLA - 72 MCG/CAPSULE | linaclotide | A06AX | Oral Solid/Capsule | blank | Does Not Trigger |
| 02417162 | CONSTELLA - 145 MCG/CAPSULE | linaclotide | A06AX | Oral Solid/Capsule | blank | Does Not Trigger |
| 02417170 | CONSTELLA - 290 MCG/CAPSULE | linaclotide | A06AX | Oral Solid/Capsule | blank | Within Guidelines |
| 02436329 | ELLA - 30 MG/TABLET | ulipristal acetate | G03XB | Oral Solid/Tablet | blank | Within Guidelines |
| 02440970 | FETZIMA - 20 MG/CAPSULE | levomilnacipran | N06AX | Oral Solid/Capsule | blank | Does Not Trigger |
| 02440989 | FETZIMA - 40 MG/CAPSULE | levomilnacipran | N06AX | Oral Solid/Capsule | blank | Does Not Trigger |
| 02440997 | FETZIMA - 80 MG/CAPSULE | levomilnacipran | N06AX | Oral Solid/Capsule | blank | Does Not Trigger |
| 02441004 | FETZIMA - 120 MG/CAPSULE | levomilnacipran | N06AX | Oral Solid/Capsule | blank | Does Not Trigger |
| 02408163 | FIBRISTAL - 5 MG/TABLET | ulipristal acetate | G03XB | Oral Solid/Tablet | blank | Within Guidelines |
| 02350939 | LATISSE - 0.3 MG/MILLILITER | bimatoprost | S01EE | Topical/Liquid | blank | Within Guidelines |
| 02417456 | LOLO 1/0.1 | norethindrone acetate/ethinyl estradiol/ethinyl estradiol | G03AB | Oral Solid/Tablet | blank | Does Not Trigger |
| 02324997 | LUMIGAN - 0.1 MG/MILLILITER | bimatoprost | S01EE | Ophthalmic/Liquid | blank | Within Guidelines |
| 02254735 | OXYTROL - 36 MG/PATCH | oxybutynin | G04BD | Topical/Patches | blank | Does Not Trigger |
| 02363445 | OZURDEX - 0.7 MG/IMPLANT | dexamethasone | S01BA | Ophthalmic/Modified release ocular devices | blank | Within Guidelines |
| 02361663 | RAPAFLO - 4 MG/CAPSULE | silodosin | G04CA | Oral Solid/Capsule | blank | Within Guidelines |
| 02361671 | RAPAFLO - 8 MG/CAPSULE | silodosin | G04CA | Oral Solid/Capsule | blank | Within Guidelines |
| 02355655 | RESTASIS - 0.2 MG/VIAL | cyclosporine | S01XA | Ophthalmic/Liquid | blank | Does Not Trigger |
| 02476835 | RESTASIS MULTIDOSE - 0.5 MG/MILLILITER | cyclosporine | S01XA | Ophthalmic/Liquid | blank | Does Not Trigger |
| 08000454 | TEFLARO - 600 MG/VIAL | ceftaroline fosamil | J01DI | Parenteral/Powder for solution | blank | Does Not Trigger |
| 02460890 | VIBERZI - 75 MG/TABLET | eluxadoline | A07DA | Oral Solid/Tablet | blank | Within Guidelines |
| 02460904 | VIBERZI - 100 MG/TABLET | eluxadoline | A07DA | Oral Solid/Tablet | blank | Within Guidelines |
Alnylam Pharmaceuticals, Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02506343 | GIVLAARI - 189 MG/MILLILITER | givosiran | A16AX | Parenteral/Solution | Introduced | Within Guidelines |
| 02489252 | ONPATTRO - 2 MG/MILLILITER | patisiran | N07XX | Parenteral/Solution | blank | VCU |
Altius Healthcare Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02441853 | PANTOPRAZOLE MAGNESIUM - 40 MG/TABLET | pantoprazole magnesium | A02BC | Oral Solid/Tablet | blank | Within Guidelines |
Amgen Canada Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02450283 | BLINCYTO - 38.5 MCG/VIAL | blinatumomab | L01XC | Parenteral/Powder for solution | blank | Within Guidelines |
| 02242903 | ENBREL - 25 MG/VIAL | etanercept | L04AA | Parenteral/Solution | blank | Within Guidelines |
| 02274728 | ENBREL - 50 MG/MILLILITER | etanercept | L04AA | Parenteral/Solution | blank | Within Guidelines |
| 02489597 | EVENITY - 105 MG/SYRINGE | romosozumab | M05BX | Parenteral/Solution | blank | Within Guidelines |
| 02496690 | KANJINTI - 420 MG/VIAL | trastuzumab | L01XC | Parenteral/Powder for solution | Introduced | Within Guidelines |
| 02459930 | KYPROLIS - 10 MG/VIAL | carfilzomib | L01XX | Parenteral/Powder for solution | blank | Within Guidelines |
| 02459949 | KYPROLIS - 30 MG/VIAL | carfilzomib | L01XX | Parenteral/Powder for solution | blank | Within Guidelines |
| 02451034 | KYPROLIS - 60 MG/VIAL | carfilzomib | L01XX | Parenteral/Powder for solution | blank | Within Guidelines |
| 02249790 | NEULASTA - 10 MG/MILLILITER | pegfilgrastim | L03AA | Parenteral/Solution | blank | Within Guidelines |
| 01968017 | NEUPOGEN - 0.3 MG/MILLILITER | filgrastim | L03AA | Parenteral/Solution | blank | Within Guidelines |
| 02420104 | NEUPOGEN - 0.6 MG/MILLILITER | filgrastim | L03AA | Parenteral/Solution | blank | Does Not Trigger |
| 02420112 | NEUPOGEN - 0.6 MG/MILLILITER | filgrastim | L03AA | Parenteral/Solution | blank | Within Guidelines |
| 02322854 | NPLATE - 250 MCG/VIAL | romiplostim | B02BX | Parenteral/Powder for solution | blank | Does Not Trigger |
| 02322862 | NPLATE - 500 MCG/VIAL | romiplostim | B02BX | Parenteral/Powder for solution | blank | Does Not Trigger |
| 02343541 | PROLIA - 60 MG/SYRINGE | denosumab | M05BX | Parenteral/Solution | blank | Within Guidelines |
| 02459779 | REPATHA - 120 MG/MILLILITER | evolocumab | C10AX | Parenteral/Solution | blank | Within Guidelines |
| 02446057 | REPATHA - 140 MG/SYRINGE | evolocumab | C10AX | Parenteral/Solution | blank | Within Guidelines |
| 02257130 | SENSIPAR - 30 MG/TABLET | cinacalcet hydrochloride | H05BX | Oral Solid/Tablet | blank | Within Guidelines |
| 02257149 | SENSIPAR - 60 MG/TABLET | cinacalcet hydrochloride | H05BX | Oral Solid/Tablet | blank | Does Not Trigger |
| 02257157 | SENSIPAR - 90 MG/TABLET | cinacalcet hydrochloride | H05BX | Oral Solid/Tablet | blank | Does Not Trigger |
| 02308487 | VECTIBIX - 20 MG/MILLILITER | panitumumab | L01XC | Parenteral/Solution | blank | Within Guidelines |
| 02308509 | VECTIBIX - 20 MG/MILLILITER | panitumumab | L01XC | Parenteral/Solution | blank | Within Guidelines |
| 02368153 | XGEVA - 120 MG/VIAL | denosumab | M05BX | Parenteral/Solution | blank | Within Guidelines |
Amicus Therapeutics Uk Ltd.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02468042 | GALAFOLD - 123 MG/CAPSULE | migalastat hydrochloride | A16AX | Oral Solid/Capsule | blank | Subj. Investigation |
Aralez Pharmaceuticals Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02454130 | BLEXTEN - 20 MG/TABLET | bilastine | R06AX | Oral Solid/Tablet | blank | Subj. Investigation |
| 02381680 | CAMBIA - 50 MG/SACHET | diclofenac potassium | M01AB | Oral Liquid/Powder for solution | blank | Within Guidelines |
| 02373017 | DURELA - 100 MG/CAPSULE | tramadol hydrochloride | N02AX | Oral Solid/Modified release capsules | blank | Within Guidelines |
| 02373025 | DURELA - 200 MG/CAPSULE | tramadol hydrochloride | N02AX | Oral Solid/Modified release capsules | blank | Within Guidelines |
| 02373033 | DURELA - 300 MG/CAPSULE | tramadol hydrochloride | N02AX | Oral Solid/Modified release capsules | blank | Within Guidelines |
| 02496305 | SUVEXX 85/500 MG/TABLET | sumatriptan/naproxen sodium | N02CC | Oral Solid/Tablet | Introduced | Under Review |
Aspen Pharmacare Canada Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02245531 | ARIXTRA - 2.5 MG/SYRINGE | fondaparinux sodium | B01AX | Parenteral/Solution | Expired | Within Guidelines |
| 02258056 | ARIXTRA - 7.5 MG/MILLILITER | fondaparinux sodium | B01AX | Parenteral/Solution | Expired | Within Guidelines |
Astellas Pharma Canada Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02294222 | MYCAMINE - 50 MG/VIAL | micafungin sodium | J02AX | Parenteral/Powder for solution | Expired | Does Not Trigger |
| 02311054 | MYCAMINE - 100 MG/VIAL | micafungin sodium | J02AX | Parenteral/Powder for solution | Expired | Within Guidelines |
| 02402874 | MYRBETRIQ - 25 MG/TABLET | mirabegron | G04BD | Oral Solid/Modified release tablets | blank | Within Guidelines |
| 02402882 | MYRBETRIQ - 50 MG/TABLET | mirabegron | G04BD | Oral Solid/Modified release tablets | blank | Within Guidelines |
| 02495058 | XOSPATA - 40 MG/TABLET | gilteritinib | L01XE | Oral Solid/Tablet | Introduced | Subj. Investigation |
| 02407329 | XTANDI - 40 MG/CAPSULE | enzalutamide | L02BB | Oral Solid/Capsule | blank | Within Guidelines |
Astrazeneca Canada Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02455005 | BRILINTA - 60 MG/TABLET | ticagrelor | B01AC | Oral Solid/Tablet | blank | Within Guidelines |
| 02368544 | BRILINTA - 90 MG/TABLET | ticagrelor | B01AC | Oral Solid/Tablet | blank | Within Guidelines |
| 02448610 | BYDUREON - 2 MG/DOSE | exenatide | A10BX | Parenteral/Modified release injections | blank | Does Not Trigger |
| 02361809 | BYETTA - 5 MCG/DOSE | exenatide | A10BX | Parenteral/Solution | blank | Does Not Trigger |
| 02361817 | BYETTA - 10 MCG/DOSE | exenatide | A10BX | Parenteral/Solution | blank | Does Not Trigger |
| 02491788 | CALQUENCE - 100 MG/CAPSULE | acalabrutinib | L01XE | Oral Solid/Capsule | blank | Within Guidelines |
| 02265540 | CRESTOR - 5 MG/TABLET | rosuvastatin calcium | C10AA | Oral Solid/Tablet | Expired | Within Guidelines |
| 02247162 | CRESTOR - 10 MG/TABLET | rosuvastatin calcium | C10AA | Oral Solid/Tablet | Expired | Within Guidelines |
| 02247163 | CRESTOR - 20 MG/TABLET | rosuvastatin calcium | C10AA | Oral Solid/Tablet | Expired | Within Guidelines |
| 02247164 | CRESTOR - 40 MG/TABLET | rosuvastatin calcium | C10AA | Oral Solid/Tablet | Expired | Within Guidelines |
| 02359456 | DAXAS - 500 MCG/TABLET | roflumilast | R03DX | Oral Solid/Tablet | Expired | Within Guidelines |
| 02439530 | DUAKLIR GENUAIR 400/12 | aclidinium bromide/formoterol fumarate dihydrate | R03AL | Pulmonary/Powder | blank | Within Guidelines |
| 02473232 | FASENRA - 30 MG/DOSE | benralizumab | R03DX | Parenteral/Solution | blank | Within Guidelines |
| 02248624 | FASLODEX - 250 MG/SYRINGE | fulvestrant | L02BA | Parenteral/Solution | Expired | Subj. Investigation |
| 02426544 | FLUMIST QUADRIVALENT - 0.2 UNIT/DOSE | influenza vaccine (live, attenuated) | J07BB | Nasal/Spray | blank | Subj. Investigation |
| 02435462 | FORXIGA - 5 MG/TABLET | dapagliflozin propanediol monohydrate | A10BX | Oral Solid/Tablet | blank | Within Guidelines |
| 02435470 | FORXIGA - 10 MG/TABLET | dapagliflozin propanediol monohydrate | A10BX | Oral Solid/Tablet | blank | Within Guidelines |
| 02468816 | IMFINZI - 50 MG/MILLILITER | durvalumab | L01XC | Parenteral/Solution | blank | Within Guidelines |
| 02248676 | IRESSA - 250 MG/TABLET | gefitinib | L01XX | Oral Solid/Tablet | Expired | Within Guidelines |
| 02389169 | KOMBOGLYZE 500/2.5 MG/TABLET | saxagliptin/metformin | A10BD | Oral Solid/Tablet | blank | Within Guidelines |
| 02389177 | KOMBOGLYZE 850/2.5 MG/TABLET | saxagliptin/metformin | A10BD | Oral Solid/Tablet | blank | Within Guidelines |
| 02389185 | KOMBOGLYZE 1000/2.5 MG/TABLET | saxagliptin/metformin | A10BD | Oral Solid/Tablet | blank | Within Guidelines |
| 02490714 | LOKELMA - 5 G/SACHET | sodium zirconium cyclosilicate | V03AE | Parenteral/Powder for suspension | Introduced | Subj. Investigation |
| 02490722 | LOKELMA - 10 G/SACHET | sodium zirconium cyclosilicate | V03AE | Parenteral/Powder for suspension | Introduced | Subj. Investigation |
| 02454408 | LYNPARZA - 50 MG/CAPSULE | olaparib | L01XX | Oral Solid/Capsule | blank | Does Not Trigger |
| 02475200 | LYNPARZA - 100 MG/TABLET | olaparib | L01XX | Oral Solid/Tablet | blank | Within Guidelines |
| 02475219 | LYNPARZA - 150 MG/TABLET | olaparib | L01XX | Oral Solid/Tablet | blank | Within Guidelines |
| 02375842 | ONGLYZA - 2.5 MG/TABLET | saxagliptin | A10BH | Oral Solid/Tablet | blank | Within Guidelines |
| 02333554 | ONGLYZA - 5 MG/TABLET | saxagliptin | A10BH | Oral Solid/Tablet | blank | Within Guidelines |
| 02237225 | OXEZE TURBUHALER - 0.006 MG/DOSE | formoterol fumarate dihydrate | R03AC | Pulmonary/Powder | blank | Within Guidelines |
| 02237224 | OXEZE TURBUHALER - 0.012 MG/DOSE | formoterol fumarate dihydrate | R03AC | Pulmonary/Powder | blank | Within Guidelines |
| 02245385 | SYMBICORT 100/6 TURBUHALER | budesonide/formoterol fumarate dihydrate | R03AK | Pulmonary/Powder | blank | Within Guidelines |
| 02245386 | SYMBICORT 200/6 TURBUHALER | budesonide/formoterol fumarate dihydrate | R03AK | Pulmonary/Powder | blank | Within Guidelines |
| 02456214 | TAGRISSO - 40 MG/TABLET | osimertinib | L01XE | Oral Solid/Tablet | blank | Does Not Trigger |
| 02456222 | TAGRISSO - 80 MG/TABLET | osimertinib | L01XE | Oral Solid/Tablet | blank | Does Not Trigger |
| 02409720 | TUDORZA GENUAIR - 400 MCG/DOSE | aclidinium bromide | R03BB | Pulmonary/Powder | blank | Within Guidelines |
| 02361701 | VIMOVO 20/375 MG/TABLET | naproxen/esomeprazole magnesium trihydrate | M01AE | Oral Solid/Modified release tablets | blank | Within Guidelines |
| 02361728 | VIMOVO 20/500 MG/TABLET | naproxen/esomeprazole magnesium trihydrate | M01AE | Oral Solid/Modified release tablets | blank | Within Guidelines |
| 02449935 | XIGDUO 5/850 MG/TABLET | dapagliflozin/metformin hydrochloride | A10BD | Oral Solid/Tablet | blank | Within Guidelines |
| 02449943 | XIGDUO 5/1000 MG/TABLET | dapagliflozin/metformin hydrochloride | A10BD | Oral Solid/Tablet | blank | Within Guidelines |
| 02238660 | ZOMIG - 2.5 MG/TABLET | zolmitriptan | N02CC | Oral Solid/Tablet | Expired | Within Guidelines |
| 02248992 | ZOMIG NASAL SPRAY - 2.5 MG/DOSE | zolmitriptan | N02CC | Nasal/Spray | Expired | Within Guidelines |
| 02248993 | ZOMIG NASAL SPRAY - 5 MG/DOSE | zolmitriptan | N02CC | Nasal/Spray | Expired | Within Guidelines |
| 02243045 | ZOMIG RAPIMELT - 2.5 MG/TABLET | zolmitriptan | N02CC | Oral Solid/Tablet | Expired | Within Guidelines |
Avir Pharma Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02483971 | CRESEMBA - 100 MG/CAPSULE | isavuconazole | J02AC | Oral Solid/Capsule | blank | Within Guidelines |
| 02483998 | CRESEMBA - 200 MG/VIAL | isavuconazole | J02AC | Parenteral/Powder for solution | blank | Within Guidelines |
| 02446685 | ZEVTERA - 500 MG/VIAL | ceftobiprole medocaril sodium | J01DI | Parenteral/Powder for solution | blank | Within Guidelines |
B
Bausch Health, Canada Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02281074 | ACZONE - 50 MG/GRAM | dapsone | D10AX | Topical/Gel | blank | Does Not Trigger |
| 02336847 | BESIVANCE - 6 MG/MILLILITER | besifloxacin | S01AX | Ophthalmic/Suspension | blank | Within Guidelines |
| 02359685 | BIACNA 1.2/0.025 | clindamycin phosphate/tretinoin | D10AF | Topical/Gel | blank | Does Not Trigger |
| 02472945 | CONTRAVE 8/90 MG/TABLET | naltrexone hcl/bupropion hcl | A08AA | Oral Solid/Tablet | blank | Within Guidelines |
| 02499967 | DUOBRII 0.1/0.45 MG/MILLILITER | halobetasol propionate/tazarotene | D05AX | Topical/Lotion | Introduced | Under Review |
| 02381389 | EDARBI - 40 MG/TABLET | azilsartan medoxomil | C09CA | Oral Solid/Tablet | blank | Within Guidelines |
| 02381397 | EDARBI - 80 MG/TABLET | azilsartan medoxomil | C09CA | Oral Solid/Tablet | blank | Does Not Trigger |
| 02397749 | EDARBYCLOR 40/12.5 MG/TABLET | azilsartan medoxomil/chlorthalidone | C09DA | Oral Solid/Tablet | blank | Subj. Investigation |
| 02397765 | EDARBYCLOR 40/25 MG/TABLET | azilsartan medoxomil/chlorthalidone | C09DA | Oral Solid/Tablet | blank | Does Not Trigger |
| 02268493 | GLUMETZA - 500 MG/TABLET | metformin hydrochloride | A10BA | Oral Solid/Modified release tablets | blank | Within Guidelines |
| 02300451 | GLUMETZA - 1000 MG/TABLET | metformin hydrochloride | A10BA | Oral Solid/Modified release tablets | blank | Within Guidelines |
| 02413388 | JUBLIA - 100 MG/GRAM | efinaconazole | D01AC | Topical/Liquid | blank | Within Guidelines |
| 02432463 | LODALIS - 3.75 G/DOSE | colesevelam hydrochloride | C10AC | Parenteral/Powder for solution | blank | Does Not Trigger |
| 02373955 | LODALIS - 625 MG/TABLET | colesevelam hydrochloride | C10AC | Oral Solid/Tablet | blank | Within Guidelines |
| 02125226 | NIDAGEL - 7.5 MG/GRAM | metronidazole | G01AF | Vaginal/Gel | blank | Within Guidelines |
| 02439123 | PROLENSA - 0.7 MG/MILLILITER | bromfenac | S01BC | Ophthalmic/Drops | blank | Within Guidelines |
| 02299194 | RALIVIA - 100 MG/TABLET | tramadol hydrochloride | N02AX | Oral Solid/Modified release tablets | blank | Within Guidelines |
| 02299208 | RALIVIA - 200 MG/TABLET | tramadol hydrochloride | N02AX | Oral Solid/Modified release tablets | blank | Does Not Trigger |
| 02299216 | RALIVIA - 300 MG/TABLET | tramadol hydrochloride | N02AX | Oral Solid/Modified release tablets | blank | Does Not Trigger |
| 02473623 | SILIQ - 210 MG/SYRINGE | brodalumab | L04AC | Parenteral/Solution | blank | Within Guidelines |
| 02256738 | TIAZAC XC - 120 MG/TABLET | diltiazem hydrochloride | C08DB | Oral Solid/Modified release tablets | Expired | Within Guidelines |
| 02256746 | TIAZAC XC - 180 MG/TABLET | diltiazem hydrochloride | C08DB | Oral Solid/Modified release tablets | Expired | Within Guidelines |
| 02256754 | TIAZAC XC - 240 MG/TABLET | diltiazem hydrochloride | C08DB | Oral Solid/Modified release tablets | Expired | Within Guidelines |
| 02256762 | TIAZAC XC - 300 MG/TABLET | diltiazem hydrochloride | C08DB | Oral Solid/Modified release tablets | Expired | Within Guidelines |
| 02256770 | TIAZAC XC - 360 MG/TABLET | diltiazem hydrochloride | C08DB | Oral Solid/Modified release tablets | Expired | Within Guidelines |
| 02365561 | VYLOMA - 37.5 MG/GRAM | imiquimod | D06BB | Topical/Cream | blank | Within Guidelines |
| 02484218 | VYZULTA - 0.24 MG/MILLILITER | latanoprostene bunod | S01EE | Ophthalmic/Solution | blank | Within Guidelines |
| 02275090 | WELLBUTRIN XL - 150 MG/TABLET | bupropion hydrochloride | N07BA | Oral Solid/Modified release tablets | blank | Subj. Investigation |
| 02275104 | WELLBUTRIN XL - 300 MG/TABLET | bupropion hydrochloride | N07BA | Oral Solid/Modified release tablets | blank | Within Guidelines |
| 02340445 | ZYCLARA - 250 MG/POUCH | imiquimod | D06BB | Topical/Cream | blank | Does Not Trigger |
Baxter Corporation
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02188880 | BREVIBLOC - 10 MG/MILLILITER | esmolol hydrochloride | C07AB | Parenteral/Solution | blank | Does Not Trigger |
| 02309238 | BREVIBLOC - 10 MG/MILLILITER | esmolol hydrochloride | C07AB | Parenteral/Solution | blank | Does Not Trigger |
Bayer Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02412764 | ADEMPAS - 0.5 MG/TABLET | riociguat | C02KX | Oral Solid/Tablet | blank | Within Guidelines |
| 02412772 | ADEMPAS - 1 MG/TABLET | riociguat | C02KX | Oral Solid/Tablet | blank | Within Guidelines |
| 02412799 | ADEMPAS - 1.5 MG/TABLET | riociguat | C02KX | Oral Solid/Tablet | blank | Within Guidelines |
| 02412802 | ADEMPAS - 2 MG/TABLET | riociguat | C02KX | Oral Solid/Tablet | blank | Within Guidelines |
| 02412810 | ADEMPAS - 2.5 MG/TABLET | riociguat | C02KX | Oral Solid/Tablet | blank | Within Guidelines |
| 02268825 | ANGELIQ 1/1 MG/TABLET | drospirenone/estradiol 17ß | G03FA | Oral Solid/Tablet | blank | Within Guidelines |
| 02246414 | AVELOX - 1.6 MG/MILLILITER | moxifloxacin hydrochloride | J01MA | Parenteral/Solution | Expired | Within Guidelines |
| 02242965 | AVELOX - 400 MG/TABLET | moxifloxacin hydrochloride | J01MA | Oral Solid/Tablet | Expired | Within Guidelines |
| 02247916 | CIPRO XL - 500 MG/TABLET | ciprofloxacin hydrochloride | J01MA | Oral Solid/Modified release tablets | blank | Subj. Investigation |
| 02251787 | CIPRO XL - 1000 MG/TABLET | ciprofloxacin hydrochloride | J01MA | Oral Solid/Modified release tablets | blank | Does Not Trigger |
| 02505355 | EYLEA - 40 MG/MILLILITER | aflibercept | S01LA | Otic/Solution | Introduced | Within Guidelines |
| 02415992 | EYLEA - 40 MG/MILLILITER | aflibercept | S01LA | Pulmonary/Solution | blank | Within Guidelines |
| 02241089 | GADOVIST 1.0 - 604.72 MG/MILLILITER | gadobutrol | V08CA | Parenteral/Solution | blank | Within Guidelines |
| 02481790 | JIVI | antihemophilic factor (recombinant, b-domain deleted, pegylated) | B02BD | Parenteral/Powder for solution | Introduced | Does Not Trigger |
| 02481782 | JIVI | antihemophilic factor (recombinant, b-domain deleted, pegylated) | B02BD | Parenteral/Powder for solution | Introduced | Within Guidelines |
| 02481774 | JIVI | antihemophilic factor (recombinant, b-domain deleted, pegylated) | B02BD | Parenteral/Powder for solution | Introduced | Does Not Trigger |
| 02481766 | JIVI | antihemophilic factor (recombinant, b-domain deleted, pegylated) | B02BD | Parenteral/Powder for solution | Introduced | Within Guidelines |
| 02451441 | KOVALTRY | antihemophilic factor (recombinant) | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02451468 | KOVALTRY | antihemophilic factor (recombinant) | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02451476 | KOVALTRY | antihemophilic factor (recombinant) | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02451484 | KOVALTRY | antihemophilic factor (recombinant) | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02451492 | KOVALTRY | antihemophilic factor (recombinant) | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02250462 | LEVITRA - 5 MG/TABLET | vardenafil hydrochloride | G04BE | Oral Solid/Tablet | blank | Does Not Trigger |
| 02250470 | LEVITRA - 10 MG/TABLET | vardenafil hydrochloride | G04BE | Oral Solid/Tablet | blank | Within Guidelines |
| 02250489 | LEVITRA - 20 MG/TABLET | vardenafil hydrochloride | G04BE | Oral Solid/Tablet | blank | Within Guidelines |
| 02284227 | NEXAVAR - 200 MG/TABLET | sofarenib tosylate | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02496348 | NUBEQA - 300 MG/TABLET | darolutamide | L02BB | Oral Solid/Tablet | Introduced | Subj. Investigation |
| 02266121 | SATIVEX 27/25 MG/MILLILITER | delta-9-tetrahydrocannabinol/cannabidiol | N02BG | Dental - Sublingual Buccal/Sprays - Buccal | blank | Subj. Investigation |
| 02372436 | STAXYN - 10 MG/TABLET | vardenafil hydrochloride | G04BE | Oral Solid/Tablet | blank | Within Guidelines |
| 02403390 | STIVARGA - 40 MG/TABLET | regorafenib | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02490331 | VITRAKVI - 20 MG/MILLILITER | larotrectinib | L01XE | Oral Liquid/Solution | blank | Within Guidelines |
| 02490315 | VITRAKVI - 25 MG/CAPSULE | larotrectinib | L01XE | Oral Solid/Capsule | Introduced | Under Review |
| 02490323 | VITRAKVI - 100 MG/CAPSULE | larotrectinib | L01XE | Oral Solid/Capsule | Introduced | Under Review |
| 02480808 | XARELTO - 2.5 MG/TABLET | rivaroxaban | B01AF | Oral Solid/Tablet | blank | Within Guidelines |
| 02316986 | XARELTO - 10 MG/TABLET | rivaroxaban | B01AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02378604 | XARELTO - 15 MG/TABLET | rivaroxaban | B01AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02378612 | XARELTO - 20 MG/TABLET | rivaroxaban | B01AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02418398 | XOFIGO - 1000 KBQ/MILLILITER | radium ra 223 dichloride | V10XX | Parenteral/Solution | blank | Within Guidelines |
| 02261723 | YASMIN 21 3/0.03 | drospirenone/ethinyl estradiol | G03AA | Oral Solid/Tablet | blank | Subj. Investigation |
| 02261731 | YASMIN 28 3/0.03 | drospirenone/ethinyl estradiol | G03AA | Oral Solid/Tablet | blank | Within Guidelines |
| 02321157 | YAZ 28 3/0.02 | drospirenone/ethinyl estradiol | G03AA | Oral Solid/Tablet | blank | Does Not Trigger |
| 02387433 | YAZ PLUS | drospirenone/ethinyl estradiol/levomefolate calcium/levomefolate calcium | G03AA | Oral Solid/Tablet | blank | Within Guidelines |
BGP Pharma ULC
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02249499 | ANDROGEL 1% - 1.25 G/DOSE | testosterone | G03BA | Topical/Gel | blank | Within Guidelines |
| 02245345 | ANDROGEL 1% - 2.5 G/POUCH | testosterone | G03BA | Topical/Gel | blank | Within Guidelines |
| 02245346 | ANDROGEL 1% - 5 G/POUCH | testosterone | G03BA | Topical/Gel | blank | Within Guidelines |
| 02146908 | BIAXIN - 25 MG/MILLILITER | clarithromycin | J01FA | Oral Liquid/Powder for suspension | blank | Subj. Investigation |
| 02244641 | BIAXIN - 50 MG/MILLILITER | clarithromycin | J01FA | Oral Liquid/Powder for suspension | blank | Subj. Investigation |
| 01984853 | BIAXIN - 250 MG/TABLET | clarithromycin | J01FA | Oral Solid/Tablet | blank | Does not Trigger |
| 02126710 | BIAXIN - 500 MG/TABLET | clarithromycin | J01FA | Oral Solid/Tablet | blank | Subj. Investigation |
| 02445158 | CREON MINIMICROSPHERES MICRO - 5000 UNIT/DOSE | pancreatin | A09AA | Oral Solid/Granules | blank | Within Guidelines |
| 02200104 | CREON MINIMICROSPHERES 10 - 10000 UNIT/CAPSULE | pancreatin | A09AA | Oral Solid/Capsule | blank | Subj. Investigation |
| 01985205 | CREON MINIMICROSPHERES 25 - 25000 UNIT/CAPSULE | pancreatin | A09AA | Oral Solid/Capsule | blank | Subj. Investigation |
| 02432889 | DYMISTA 137/50 MCG/DOSE | azelastine hydrochloride/fluticasone propionate | R01AD | Nasal/Solution | blank | Within Guidelines |
| 02269074 | LIPIDIL EZ - 48 MG/TABLET | fenofibrate | C10AB | Oral Solid/Tablet | blank | Within Guidelines |
| 02269082 | LIPIDIL EZ - 145 MG/TABLET | fenofibrate | C10AB | Oral Solid/Tablet | blank | Within Guidelines |
| 02241602 | LIPIDIL SUPRA - 160 MG/TABLET | fenofibrate | C10AB | Oral Solid/Tablet | blank | Subj. Investigation |
| 02231457 | MAVIK - 0.5 MG/CAPSULE | trandolapril | C09AA | Oral Solid/Capsule | Expired | Subj. Investigation |
| 02231459 | MAVIK - 1 MG/CAPSULE | trandolapril | C09AA | Oral Solid/Capsule | Expired | Subj. Investigation |
| 02231460 | MAVIK - 2 MG/CAPSULE | trandolapril | C09AA | Oral Solid/Capsule | Expired | Subj. Investigation |
| 02239267 | MAVIK - 4 MG/CAPSULE | trandolapril | C09AA | Oral Solid/Capsule | Expired | Subj. Investigation |
| 02365154 | TOBI PODHALER - 28 MG/CAPSULE | tobramycin | J01GB | Pulmonary/Powder | blank | Within Guidelines |
Biogen Canada Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02269201 | AVONEX PS - 30 MCG/SYRINGE | interferon beta-1a | L03AB | Parenteral/Solution | blank | Within Guidelines |
| 02379910 | FAMPYRA - 10 MG/TABLET | fampridine | N07XX | Oral Solid/Modified release tablets | blank | Does Not Trigger |
| 02444402 | PLEGRIDY | peginterferon beta-1a | L03AB | Parenteral/Solution | blank | Within Guidelines |
| 02444399 | PLEGRIDY - 125 MCG/SYRINGE | peginterferon beta-1a | L03AB | Parenteral/Solution | blank | Subj. Investigation |
| 02465663 | SPINRAZA - 2.4 MG/MILLILITER | nusinersen sodium | M09AX | Parenteral/Solution | blank | Within Guidelines |
| 02404508 | TECFIDERA - 120 MG/CAPSULE | dimethyl fumarate | L04AX | Oral Solid/Capsule | blank | Within Guidelines |
| 02420201 | TECFIDERA - 240 MG/CAPSULE | dimethyl fumarate | L04AX | Oral Solid/Capsule | blank | Within Guidelines |
| 02286386 | TYSABRI - 20 MG/MILLILITER | natalizumab | L04AA | Parenteral/Powder for solution | blank | Within Guidelines |
Biomarin Pharmaceutical Canada Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02484013 | BRINEURA - 300 MG/PACK | cerliponase alfa | A16AB | Parenteral/Solution | blank | Within Guidelines |
| 02350580 | KUVAN - 100 MG/TABLET | sapropterin dihydrochloride | A16AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02482207 | KUVAN - 100 MG/SACHET | sapropterin dihydrochloride | A16AX | Oral Liquid/Powder for solution | Introduced | Within Guidelines |
| 02482215 | KUVAN - 500 MG/SACHET | sapropterin dihydrochloride | A16AX | Oral Liquid/Powder for solution | Introduced | Within Guidelines |
| 02412683 | NAGLAZYME - 1 MG/MILLILITER | galsulfase | A16AB | Parenteral/Solution | blank | Within Guidelines |
Bioverativ Canada Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02422913 | ALPROLIX - 500 IU/VIAL | coagulation factor ix (recombinant), fc fusion protein | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02422921 | ALPROLIX - 1000 IU/VIAL | coagulation factor ix (recombinant), fc fusion protein | B02BD | Parenteral/Powder for solution | blank | Does Not Trigger |
| 02422948 | ALPROLIX - 2000 IU/VIAL | coagulation factor ix (recombinant), fc fusion protein | B02BD | Parenteral/Powder for solution | blank | Subj. Investigation |
| 02422956 | ALPROLIX - 3000 IU/VIAL | coagulation factor ix (recombinant), fc fusion protein | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02430304 | ELOCTATE - 500 IU/VIAL | antihemophilic factor (recombinant bdd), fc fusion protein | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02430312 | ELOCTATE - 750 IU/VIAL | antihemophilic factor (recombinant bdd), fc fusion protein | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02430320 | ELOCTATE - 1000 IU/VIAL | antihemophilic factor (recombinant bdd), fc fusion protein | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02430339 | ELOCTATE - 1500 IU/VIAL | antihemophilic factor (recombinant bdd), fc fusion protein | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02430347 | ELOCTATE - 2000 IU/VIAL | antihemophilic factor (recombinant bdd), fc fusion protein | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02430355 | ELOCTATE - 3000 IU/VIAL | antihemophilic factor (recombinant bdd), fc fusion protein | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
Boehringer Ingelheim (Canada) Ltd.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02419106 | COMBIVENT RESPIMAT 20/100 MCG/ACTUATION | ipratropium bromide monohydrate/salbutamol sulfate | R03AL | Pulmonary/Solution | blank | Subj. Investigation |
| 02415666 | GIOTRIF - 20 MG/TABLET | afatinib | L01XE | Oral Solid/Tablet | blank | Subj. Investigation |
| 02415674 | GIOTRIF - 30 MG/TABLET | afatinib | L01XE | Oral Solid/Tablet | blank | Subj. Investigation |
| 02415682 | GIOTRIF - 40 MG/TABLET | afatinib | L01XE | Oral Solid/Tablet | blank | Subj. Investigation |
| 02459752 | GLYXAMBI 10/5 MG/TABLET | empagliflozin/linagliptin | A10BD | Oral Solid/Tablet | blank | Within Guidelines |
| 02459760 | GLYXAMBI 25/5 MG/TABLET | empagliflozin/linagliptin | A10BD | Oral Solid/Tablet | blank | Within Guidelines |
| 02441888 | INSPIOLTO RESPIMAT 2.5/2.5 MCG/ACTUATION | tiotropium bromide monohydrate/olodaterol hydrochloride | R03BB | Pulmonary/Solution | blank | Within Guidelines |
| 02443937 | JARDIANCE - 10 MG/TABLET | empagliflozin | A10BX | Oral Solid/Tablet | blank | Does Not Trigger |
| 02443945 | JARDIANCE - 25 MG/TABLET | empagliflozin | A10BX | Oral Solid/Tablet | blank | Subj. Investigation |
| 02403250 | JENTADUETO 2.5/500 MG/TABLET | linagliptin/metformin | A10BD | Oral Solid/Tablet | blank | Within Guidelines |
| 02403269 | JENTADUETO 2.5/850 MG/TABLET | linagliptin/metformin | A10BD | Oral Solid/Tablet | blank | Within Guidelines |
| 02403277 | JENTADUETO 2.5/1000 MG/TABLET | linagliptin/metformin | A10BD | Oral Solid/Tablet | blank | Within Guidelines |
| 02240769 | MICARDIS - 40 MG/TABLET | telmisartan | C09CA | Oral Solid/Tablet | blank | Does Not Trigger |
| 02240770 | MICARDIS - 80 MG/TABLET | telmisartan | C09CA | Oral Solid/Tablet | blank | Does Not Trigger |
| 02244344 | MICARDIS PLUS 80/12.5 MG/TABLET | telmisartan/hydrochlorothiazide | C09DA | Oral Solid/Tablet | blank | Within Guidelines |
| 02318709 | MICARDIS PLUS 80/25MG/TABLET | telmisartan/hydrochlorothiazide | C09DA | Oral Solid/Tablet | blank | Within Guidelines |
| 02443066 | OFEV - 100 MG/CAPSULE | nintedanib | L01XE | Oral Solid/Capsule | blank | Subj. Investigation |
| 02443074 | OFEV - 150 MG/CAPSULE | nintedanib | L01XE | Oral Solid/Capsule | blank | Subj. Investigation |
| 02312433 | PRADAXA - 75 MG/CAPSULE | dabigatran etexilate | B01AE | Oral Solid/Capsule | blank | Within Guidelines |
| 02312441 | PRADAXA - 110 MG/CAPSULE | dabigatran etexilate | B01AE | Oral Solid/Capsule | blank | Within Guidelines |
| 02358808 | PRADAXA - 150 MG/CAPSULE | dabigatran etexilate | B01AE | Oral Solid/Capsule | blank | Within Guidelines |
| 02246793 | SPIRIVA - 18 MCG/CAPSULE | tiotropium bromide monohydrate | R03BB | Pulmonary/Powder | blank | Within Guidelines |
| 02435381 | SPIRIVA RESPIMAT - 2.5 MCG/ACTUATION | tiotropium bromide monohydrate | R03BB | Pulmonary/Solution | blank | Within Guidelines |
| 02456575 | SYNJARDY 5/500 MG/TABLET | empagliflozin/metformin hydrochloride | A10BD | Oral Solid/Tablet | blank | Within Guidelines |
| 02456583 | SYNJARDY 5/850 MG/TABLET | empagliflozin/metformin hydrochloride | A10BD | Oral Solid/Tablet | blank | Subj. Investigation |
| 02456591 | SYNJARDY 5/1000 MG/TABLET | empagliflozin/metformin hydrochloride | A10BD | Oral Solid/Tablet | blank | Does Not Trigger |
| 02456605 | SYNJARDY 12.5/500 MG/TABLET | empagliflozin/metformin hydrochloride | A10BD | Oral Solid/Tablet | blank | Does Not Trigger |
| 02456613 | SYNJARDY 12.5/850 MG/TABLET | empagliflozin/metformin hydrochloride | A10BD | Oral Solid/Tablet | blank | Subj. Investigation |
| 02456621 | SYNJARDY 12.5/1000 MG/TABLET | empagliflozin/metformin hydrochloride | A10BD | Oral Solid/Tablet | blank | Subj. Investigation |
| 02370921 | TRAJENTA - 5 MG/TABLET | linagliptin | A10BH | Oral Solid/Tablet | blank | Within Guidelines |
| 02371022 | TWYNSTA 40/5 MG/TABLET | telmisartan/amlodipine besylate | C09DB | Oral Solid/Tablet | blank | Within Guidelines |
| 02371030 | TWYNSTA 40/10 MG/TABLET | telmisartan/amlodipine besylate | C09DB | Oral Solid/Tablet | blank | Within Guidelines |
| 02371049 | TWYNSTA 80/5 MG/TABLET | telmisartan/amlodipine besylate | C09DB | Oral Solid/Tablet | blank | Within Guidelines |
| 02371057 | TWYNSTA 80/10 MG/TABLET | telmisartan/amlodipine besylate | C09DB | Oral Solid/Tablet | blank | Within Guidelines |
Bristol-Myers Squibb Canada Co.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02282224 | BARACLUDE - 0.5 MG/TABLET | entecavir | J05AF | Oral Solid/Tablet | blank | Within Guidelines |
| 02377233 | ELIQUIS - 2.5 MG/TABLET | apixaban | B01AF | Oral Solid/Tablet | blank | Within Guidelines |
| 02397714 | ELIQUIS - 5 MG/TABLET | apixaban | B01AF | Oral Solid/Tablet | blank | Within Guidelines |
| 02446626 | OPDIVO - 40 MG/VIAL | nivolumab | L01XC | Parenteral/Solution | blank | Within Guidelines |
| 02446634 | OPDIVO - 100 MG/VIAL | nivolumab | L01XC | Parenteral/Solution | blank | Within Guidelines |
| 02402475 | ORENCIA - 125 MG/SYRINGE | abatacept | L04AA | Parenteral/Solution | blank | Within Guidelines |
| 02282097 | ORENCIA - 250 MG/VIAL | abatacept | L04AA | Parenteral/Powder for solution | blank | Within Guidelines |
| 02294176 | REYATAZ - 300 MG/CAPSULE | atazanavir sulfate | J05AE | Oral Solid/Capsule | blank | Does Not Trigger |
| 02293129 | SPRYCEL - 20 MG/TABLET | dasatinib | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02293137 | SPRYCEL - 50 MG/TABLET | dasatinib | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02293145 | SPRYCEL - 70 MG/TABLET | dasatinib | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02360810 | SPRYCEL - 80 MG/TABLET | dasatinib | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02320193 | SPRYCEL - 100 MG/TABLET | dasatinib | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02360829 | SPRYCEL - 140 MG/TABLET | dasatinib | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02379384 | YERVOY - 5 MG/MILLILITER | ipilimumab | L01XC | Parenteral/Solution | blank | Within Guidelines |
C
Celgene Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02281066 | ABRAXANE - 100 MG/VIAL | nanoparticle albumin-bound paclitaxel | L01CD | Parenteral/Suspensions or Emulsions | blank | Within Guidelines |
| 02419580 | POMALYST - 1 MG/CAPSULE | pomalidomide | L04AX | Oral Solid/Capsule | blank | Within Guidelines |
| 02419599 | POMALYST - 2 MG/CAPSULE | pomalidomide | L04AX | Oral Solid/Capsule | blank | Within Guidelines |
| 02419602 | POMALYST - 3 MG/CAPSULE | pomalidomide | L04AX | Oral Solid/Capsule | blank | Within Guidelines |
| 02419610 | POMALYST - 4 MG/CAPSULE | pomalidomide | L04AX | Oral Solid/Capsule | blank | Within Guidelines |
| 02505541 | REBLOZYL - 25 MG/VIAL | luspatercept | B03XA | Parenteral/Powder for solution | Introduced | Under Review |
| 02505568 | REBLOZYL - 75 MG/VIAL | luspatercept | B03XA | Parenteral/Powder for solution | Introduced | Under Review |
| 02459418 | REVLIMID - 2.5 MG/CAPSULE | lenalidomide | L04AX | Oral Solid/Capsule | blank | Subj. Investigation |
| 02304899 | REVLIMID - 5 MG/CAPSULE | lenalidomide | L04AX | Oral Solid/Capsule | blank | Subj. Investigation |
| 02304902 | REVLIMID - 10 MG/CAPSULE | lenalidomide | L04AX | Oral Solid/Capsule | blank | Within Guidelines |
| 02317699 | REVLIMID - 15 MG/CAPSULE | lenalidomide | L04AX | Oral Solid/Capsule | blank | Does Not Trigger |
| 02440601 | REVLIMID - 20 MG/CAPSULE | lenalidomide | L04AX | Oral Solid/Capsule | blank | Does Not Trigger |
| 02317710 | REVLIMID - 25 MG/CAPSULE | lenalidomide | L04AX | Oral Solid/Capsule | blank | Within Guidelines |
| 02355191 | THALOMID - 50 MG/CAPSULE | thalidomide | L04AX | Oral Solid/Capsule | blank | Within Guidelines |
| 02355205 | THALOMID - 100 MG/CAPSULE | thalidomide | L04AX | Oral Solid/Capsule | blank | Within Guidelines |
| 02355221 | THALOMID - 200 MG/CAPSULE | thalidomide | L04AX | Oral Solid/Capsule | blank | Does Not Trigger |
| 02505991 | ZEPOSIA - 0.92 MG/CAPSULE | ozanimod | L04AA | Oral Solid/Capsule | Introduced | Under Review |
| 02506009 | ZEPOSIA 0.23/0.46 | ozanimod | L04AA | Oral Solid/Capsule | Introduced | Under Review |
Cheplapharm Arzneimittel Gmbh
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02240325 | XENICAL - 120 MG/CAPSULE | orlistat | A08AB | Oral Solid/Capsule | blank | Within Guidelines |
Chiesi USA, Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| blank | CARDENE I.V. - 20 MG/DOSE | nicardipine hydrochloride | C08CA | Parenteral/Solution | blank | Subj. Investigation |
| blank | CARDENE I.V. - 20 MG/DOSE | nicardipine hydrochloride | C08CA | Parenteral/Solution | blank | Subj. Investigation |
| blank | CARDENE I.V. - 40 MG/DOSE | nicardipine hydrochloride | C08CA | Parenteral/Solution | blank | Subj. Investigation |
| blank | CARDENE I.V. - 40 MG/DOSE | nicardipine hydrochloride | C08CA | Parenteral/Solution | blank | Subj. Investigation |
| 02366223 | CLEVIPREX - 0.5 MG/MILLILITER | clevidipine | C08CA | Parenteral/Suspensions or Emulsions | Introduced | Subj. Investigation |
Cipher Pharmaceuticals Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02462400 | BRINAVESS - 20 MG/MILLILITER | vernakalant hydrochloride | C01BG | Parenteral/Solution | blank | Does Not Trigger |
| 02463504 | OZANEX - 10 MG/GRAM | ozenoxacin | D06AX | Topical/Cream | blank | Within Guidelines |
Covis Pharma BV
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02285606 | ALVESCO - 100 MCG/DOSE | ciclesonide | R03BA | Pulmonary/Metered dose preparations | Expired | Within Guidelines |
| 02285614 | ALVESCO - 200 MCG/DOSE | ciclesonide | R03BA | Pulmonary/Metered dose preparations | Expired | Within Guidelines |
| 02303671 | OMNARIS - 50 MCG/DOSE | ciclesonide | R03BA | Nasal/Metered dose preparations | Expired | Within Guidelines |
CSL Behring Canada Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 2418738 | CORIFACT 250 - 250 IU/MILLILITER | factor xiii concentrate, human | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02418746 | CORIFACT 1250 - 1250 IU/MILLILITER | factor xiii concentrate, human | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02370352 | HIZENTRA - 200 MG/MILLILITER | subcutaneous immune globulin (human) | J06BA | Parenteral/Solution | blank | Within Guidelines |
| 02451352 | IDELVION - 1000 IU/VIAL | coagulation factor ix (recombinant), albumin fusion protein (rix-fp) | B02BD | Parenteral/Powder for solution | blank | Subj. Investigation |
| 02304619 | PRIVIGEN - 100 MG/MILLILITER | immuneglobulin (human) | J06BA | Parenteral/Solution | blank | Subj. Investigation |
D
Duchesnay Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 00609129 | DICLECTIN 10/10 MG/TABLET | doxylamine succinate/pyridoxine hydrochloride | R06AA | Oral Solid/Modified release tablets | blank | Within Guidelines |
| 02460262 | MICTORYL - 30 MG/CAPSULE | propiverine hcl | G04BD | Oral Solid/Modified release capsules | blank | Within Guidelines |
| 02460270 | MICTORYL - 45 MG/CAPSULE | propiverine hcl | G04BD | Oral Solid/Modified release capsules | blank | Within Guidelines |
| 02460289 | MICTORYL PEDIATRIC - 5 MG/TABLET | propiverine hcl | G04BD | Oral Solid/Tablet | blank | Within Guidelines |
| 02451573 | PREGVIT | multivitamins-minerals | B03AE | Oral Solid/Tablet | blank | Subj. Investigation |
| 02451581 | PREGVIT FOLIC 5 | multivitamins-minerals | B03AE | Oral Solid/Tablet | blank | Within Guidelines |
E
Eisai Limited
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02369613 | BANZEL - 100 MG/TABLET | rufinamide | N03AF | Oral Solid/Tablet | Expired | Within Guidelines |
| 02369621 | BANZEL - 200 MG/TABLET | rufinamide | N03AF | Oral Solid/Tablet | Expired | Within Guidelines |
| 02369648 | BANZEL - 400 MG/TABLET | rufinamide | N03AF | Oral Solid/Tablet | Expired | Within Guidelines |
| 02507366 | DAYVIGO - 5 MG/TABLET | lemborexant | N05CM | Oral Solid/Tablet | Introduced | Under Review |
| 02507374 | DAYVIGO - 10 MG/TABLET | lemborexant | N05CM | Oral Solid/Tablet | Introduced | Under Review |
| 02404516 | FYCOMPA - 2 MG/TABLET | perampanel | N03AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02404524 | FYCOMPA - 4 MG/TABLET | perampanel | N03AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02404532 | FYCOMPA - 6 MG/TABLET | perampanel | N03AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02404540 | FYCOMPA - 8 MG/TABLET | perampanel | N03AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02404559 | FYCOMPA - 10 MG/TABLET | perampanel | N03AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02404567 | FYCOMPA - 12 MG/TABLET | perampanel | N03AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02377438 | HALAVEN - 1 MG/VIAL | eribulin mesylate | L01XX | Parenteral/Solution | blank | Within Guidelines |
| 02484056 | LENVIMA - 4 MG/DAY | lenvatinib mesylate | L01XE | Oral Solid/Capsule | blank | Within Guidelines |
| 02468220 | LENVIMA - 8 MG/DAY | lenvatinib mesylate | L01XE | Oral Solid/Capsule | blank | Within Guidelines |
| 02450321 | LENVIMA - 10 MG/DAY | lenvatinib mesylate | L01XE | Oral Solid/Capsule | blank | Within Guidelines |
| 02484129 | LENVIMA - 12 MG/DAY | lenvatinib mesylate | L01XE | Oral Solid/Capsule | blank | Within Guidelines |
| 02468239 | LENVIMA - 18 MG/DAY | lenvatinib mesylate | L01XE | Oral Solid/Capsule | blank | Within Guidelines |
| 02450313 | LENVIMA 10/4 MG/DAY | lenvatinib mesylate | L01XE | Oral Solid/Capsule | blank | Within Guidelines |
| 02450305 | LENVIMA 10/10 MG/DAY | lenvatinib mesylate | L01XE | Oral Solid/Capsule | blank | Within Guidelines |
| 02450291 | LENVIMA 10/10/4 MG/DAY | lenvatinib mesylate | L01XE | Oral Solid/Capsule | blank | Within Guidelines |
Eli Lilly Canada Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02338327 | ADCIRCA - 20 MG/TABLET | tadalafil | C02KX | Oral Solid/Tablet | blank | Within Guidelines |
| 02306433 | ALIMTA - 100 MG/VIAL | pemetrexed sodium | L01BA | Parenteral/Powder for solution | blank | Subj. Investigation |
| 02253437 | ALIMTA - 500 MG/VIAL | pemetrexed sodium | L01BA | Parenteral/Powder for solution | blank | Subj. Investigation |
| 02296888 | CIALIS - 2.5 MG/TABLET | tadalafil | G04BE | Oral Solid/Tablet | blank | Within Guidelines |
| 02296896 | CIALIS - 5 MG/TABLET | tadalafil | G04BE | Oral Solid/Tablet | blank | Within Guidelines |
| 02248088 | CIALIS - 10 MG/TABLET | tadalafil | G04BE | Oral Solid/Tablet | blank | Within Guidelines |
| 02248089 | CIALIS - 20 MG/TABLET | tadalafil | G04BE | Oral Solid/Tablet | blank | Within Guidelines |
| 02443805 | CYRAMZA - 10 MG/MILLILITER | ramucirumab | L01XC | Parenteral/Solution | blank | Within Guidelines |
| 02349124 | EFFIENT - 10 MG/TABLET | prasugrel hydrochloride | B01AC | Oral Solid/Tablet | blank | Within Guidelines |
| 02491087 | EMGALITY - 120 MG/MILLILITER | galcanezumab | N02CX | Parenteral/Solution | blank | Subj. Investigation |
| 02491060 | EMGALITY - 120 MG/MILLILITER | galcanezumab | N02CX | Parenteral/Solution | blank | Subj. Investigation |
| 02480271 | LARTRUVO - 190 MG/VIAL | olaratumab | L01XC | Parenteral/Solution | Introduced | Under Review |
| 02469227 | LARTRUVO - 500 MG/VIAL | olaratumab | L01XC | Parenteral/Solution | blank | Within Guidelines |
| 02480018 | OLUMIANT - 2 MG/TABLET | baricitinib | L04AA | Oral Solid/Tablet | blank | Within Guidelines |
| 02455102 | TALTZ - 80 MG/MILLILITER | ixekizumab | L04AC | Parenteral/Solution | blank | VCU |
| 02455110 | TALTZ - 80 MG/MILLILITER | ixekizumab | L04AC | Parenteral/Solution | blank | Does Not Trigger |
| 02448599 | TRULICITY - 0.75 MG/PEN | dulaglutide | A10BX | Parenteral/Solution | blank | Within Guidelines |
| 02448602 | TRULICITY - 1.5 MG/PEN | dulaglutide | A10BX | Parenteral/Solution | blank | Subj. Investigation |
| 02487098 | VERZENIO - 50 MG/TABLET | abemaciclib | L01XE | Oral Solid/Tablet | blank | Does Not Trigger |
| 02487101 | VERZENIO - 100 MG/TABLET | abemaciclib | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02487128 | VERZENIO - 150 MG/TABLET | abemaciclib | L01XE | Oral Solid/Tablet | blank | Does Not Trigger |
| 02487136 | VERZENIO - 200 MG/TABLET | abemaciclib | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
Elvium Life Sciences
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02468735 | AKYNZEO 300/0.5 MG/CAPSULE | netupitant/palonosetron | A04AA | Oral Solid/Capsule | blank | Within Guidelines |
| 02381729 | ALOXI - 0.5 MG/CAPSULE | palonosetron hydrochloride | A04AA | Oral Solid/Capsule | blank | Does Not Trigger |
| 02381710 | ALOXI - 0.05 MG/MILLILITER | palonosetron hydrochloride | A04AA | Parenteral/Solution | blank | Within Guidelines |
| 02470292 | FOQUEST - 25 MG/CAPSULE | methylphenidate hydrochloride | N06BA | Oral Solid/Capsule | blank | Does Not Trigger |
| 02470306 | FOQUEST - 35 MG/CAPSULE | methylphenidate hydrochloride | N06BA | Oral Solid/Capsule | blank | Does Not Trigger |
| 02470314 | FOQUEST - 45 MG/CAPSULE | methylphenidate hydrochloride | N06BA | Oral Solid/Capsule | blank | Does Not Trigger |
| 02470322 | FOQUEST - 55 MG/CAPSULE | methylphenidate hydrochloride | N06BA | Oral Solid/Capsule | blank | Within Guidelines |
| 02470330 | FOQUEST - 70 MG/CAPSULE | methylphenidate hydrochloride | N06BA | Oral Solid/Capsule | blank | Does Not Trigger |
| 02470349 | FOQUEST - 85 MG/CAPSULE | methylphenidate hydrochloride | N06BA | Oral Solid/Capsule | blank | Within Guidelines |
| 02470357 | FOQUEST - 100 MG/CAPSULE | methylphenidate hydrochloride | N06BA | Oral Solid/Capsule | blank | Does Not Trigger |
EMD Serono Canada Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02469723 | BAVENCIO - 20 MG/MILLILITER | avelumab | L01XC | Parenteral/Solution | Expired | Within Guidelines |
| 02247766 | CETROTIDE - 0.25 MG/VIAL | cetrorelix acetate | H01CC | Parenteral/Powder for solution | Expired | Within Guidelines |
| 02248154 | GONAL-F - 75 UNIT/VIAL | follitropin alpha | G03GA | Parenteral/Powder for solution | Expired | Within Guidelines |
| 02270404 | GONAL-F PEN - 300 UNIT/PEN | follitropin alpha | G03GA | Parenteral/Solution | Expired | Within Guidelines |
| 02270390 | GONAL-F PEN - 450 UNIT/PEN | follitropin alpha | G03GA | Parenteral/Solution | Expired | Within Guidelines |
| 02270382 | GONAL-F PEN - 900 UNIT/PEN | follitropin alpha | G03GA | Parenteral/Solution | Expired | Within Guidelines |
| 02269066 | LUVERIS - 75 UNIT/VIAL | lutropin alpha | G03GA | Parenteral/Powder for solution | Expired | Subj. Investigation |
| 02470179 | MAVENCLAD - 10 MG/TABLET | cladribine | L01BB | Oral Solid/Tablet | blank | Within Guidelines |
| 02350122 | SAIZEN LIQUID - 6 MG/CARTRIDGE | somatropin | H01AC | Parenteral/Solution | Expired | Within Guidelines |
| 02350130 | SAIZEN LIQUID - 12 MG/CARTRIDGE | somatropin | H01AC | Parenteral/Solution | Expired | Within Guidelines |
| 02350149 | SAIZEN LIQUID - 20 MG/CARTRIDGE | somatropin | H01AC | Parenteral/Solution | Expired | Within Guidelines |
F
Ferring Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02455889 | CORTIMENT - 9 MG/TABLET | budesonide | A07EA | Oral Solid/Tablet | Expired | Does Not Trigger |
| 00824305 | DDAVP - 0.1 MG/TABLET | desmopressin acetate | H01BA | Oral Solid/Tablet | blank | Within Guidelines |
| 00824143 | DDAVP - 0.2 MG/TABLET | desmopressin acetate | H01BA | Oral Solid/Tablet | blank | Within Guidelines |
| 02284995 | DDAVP MELT - 60 MCG/TABLET | desmopressin acetate | H01BA | Oral Solid/Tablet | blank | Within Guidelines |
| 02285002 | DDAVP MELT - 120 MCG/TABLET | desmopressin acetate | H01BA | Oral Solid/Tablet | blank | Within Guidelines |
| 02285010 | DDAVP MELT - 240 MCG/TABLET | desmopressin acetate | H01BA | Oral Solid/Tablet | blank | Within Guidelines |
| 02334992 | ENDOMETRIN - 100 MG/TABLET | progesterone | G03DA | Vaginal/Tablet | blank | Within Guidelines |
| 02397927 | NOCDURNA - 25 MCG/TABLET | desmopressin acetate | H01BA | Dental - Sublingual Buccal/Sublingual tablets | blank | Within Guidelines |
| 02431076 | NOCDURNA - 50 MCG/TABLET | desmopressin acetate | H01BA | Dental - Sublingual Buccal/Sublingual tablets | blank | Within Guidelines |
| 02399466 | PENTASA - 1 GM/TABLET | mesalazine | A07EC | Oral Solid/Tablet | blank | Within Guidelines |
| 02099683 | PENTASA - 500 MG/TABLET | mesalazine | A07EC | Oral Solid/Tablet | blank | Within Guidelines |
G
Galderma Canada Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02494175 | AKLIEF - 50 MCG/GRAM | trifarotene | D10AD | Topical/Cream | blank | Within Guidelines |
| 02375885 | APPRILON - 40 MG/CAPSULE | doxycycline monohydrate | J01AA | Oral Solid/Modified release capsules | blank | Does Not Trigger |
| 02323273 | METVIX - 168 MG/GRAM | methyl aminolevulinate hydrochloride | L01XD | Topical/Cream | Expired | Within Guidelines |
| 02421208 | ONRELTEA - 5 MG/GRAM | brimonidine tartrate | S01EA | Topical/Gel | blank | Within Guidelines |
| 02440342 | ROSIVER - 10 MG/GRAM | ivermectin | D11AX | Topical/Cream | blank | Within Guidelines |
| 02365871 | TACTUPUMP 1/25 MG/GRAM | adapalene/benzoyl peroxide | D10AD | Topical/Gel | blank | Does Not Trigger |
| 02446235 | TACTUPUMP FORTE - 70 G/PUMP | adapalene/benzoyl peroxide | D10AD | Topical/Gel | blank | Within Guidelines |
GE Healthcare Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02470624 | DATSCAN - 74 MBQ/MILLILITER | ioflupane (123i) | V09AB | Parenteral/Solution | blank | Subj. Investigation |
Gilead Sciences Canada Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02300699 | ATRIPLA 600/200/300 MG/TABLET | efavirenz/emtricitabine/tenofovir disoproxil fumarate | J05AR | Oral Solid/Tablet | blank | Does Not Trigger |
| 02478579 | BIKTARVY 25/50/200 MG/TABLET | bictegravir/emtricitabine/tenofovir alafenamide | J05AR | Oral Solid/Tablet | blank | Within Guidelines |
| 02329840 | CAYSTON - 75 MG/VIAL | aztreonam | J01DF | Pulmonary/Powder | blank | Within Guidelines |
| 02374129 | COMPLERA 200/300/25 MG/TABLET | emtricitabine/rilpivirine/tenofovir disoproxil fumarate | J05AR | Oral Solid/Tablet | blank | Within Guidelines |
| 02454416 | DESCOVY 200/10 MG/TABLET | emtricitabine/tenofovir alafenamide | J05AR | Oral Solid/Tablet | blank | Subj. Investigation |
| 02454424 | DESCOVY 200/25 MG/TABLET | emtricitabine/tenofovir alafenamide | J05AR | Oral Solid/Tablet | blank | Subj. Investigation |
| 02456370 | EPCLUSA 400/100 MG/TABLET | sofosbuvir/velpatasvir | J05AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02449498 | GENVOYA 200/150/150/10 MG/TABLET | elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide | J05AR | Oral Solid/Tablet | blank | Within Guidelines |
| 02432226 | HARVONI 90/400 MG/TABLET | ledipasvir/sofosbuvir | J05AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02247823 | HEPSERA - 10 MG/TABLET | adefovir dipivoxil | J05AF | Oral Solid/Tablet | blank | Subj. Investigation |
| 02461463 | ODEFSEY 200/25/25 MG/TABLET | emtricitabine/rilpivirine/tenofovir alafenamide | J05AR | Oral Solid/Tablet | blank | Within Guidelines |
| 02418355 | SOVALDI - 400 MG/TABLET | sofosbuvir | J05AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02397137 | STRIBILD 150/150/200/300 MG/TABLET | elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate | J05AR | Oral Solid/Tablet | blank | Within Guidelines |
| 02274906 | TRUVADA 200/300 MG/TABLET | emtricitabine/tenofovir disoproxil fumarate | J05AR | Oral Solid/Tablet | blank | Within Guidelines |
| 02502143 | VEKLURY - 100 MG/VIAL | remdesivir | J05 | Parenteral/Powder for solution | Introduced | Under Review |
| 02464241 | VEMLIDY - 25 MG/TABLET | tenofovir alafenamide | J05AF | Oral Solid/Tablet | blank | Within Guidelines |
| 02247128 | VIREAD - 300 MG/TABLET | tenofovir disoproxil fumarate | J05AF | Oral Solid/Tablet | blank | Within Guidelines |
| 02467542 | VOSEVI 400/100/100 MG/TABLET | sofosbuvir/velpatasvir/voxilaprevir | J05AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02438798 | ZYDELIG - 100 MG/TABLET | idelalisib | L01XX | Oral Solid/Tablet | blank | Within Guidelines |
| 02438801 | ZYDELIG - 150 MG/TABLET | idelalisib | L01XX | Oral Solid/Tablet | blank | Within Guidelines |
Glaxosmithkline Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02418401 | ANORO ELLIPTA 62.5/25 MCG/DOSE | umeclidinium bromide/vilanterol trifenatate | R03AL | Pulmonary/Powder | blank | Within Guidelines |
| 02446561 | ARNUITY ELLIPTA - 100 MCG/DOSE | fluticasone furoate | R01AD | Pulmonary/Powder | blank | Within Guidelines |
| 02446588 | ARNUITY ELLIPTA - 200 MCG/DOSE | fluticasone furoate | R01AD | Pulmonary/Powder | blank | Within Guidelines |
| 02298589 | AVAMYS - 27.5 MCG/DOSE | fluticasone furoate | R01AD | Nasal/Spray | blank | Within Guidelines |
| 02370050 | BENLYSTA - 120 MG/VIAL | belimumab | L04AA | Parenteral/Powder for solution | blank | Within Guidelines |
| 02370069 | BENLYSTA - 400 MG/VIAL | belimumab | L04AA | Parenteral/Powder for solution | blank | Within Guidelines |
| 02470489 | BENLYSTA - 200 MG/MILLILITER | belimumab | L04AA | Parenteral/Solution | blank | Subj. Investigation |
| 02417030 | BEXSERO | multicomponent meningococcal b vaccine | J07AH | Parenteral/Suspensions or Emulsions | blank | Subj. Investigation |
| 02247600 | BOOSTRIX | combined diphtheria, tetanus, acellular pertussis (adsorbed) vaccine | J07AX | Parenteral/Suspensions or Emulsions | blank | Within Guidelines |
| 02312557 | BOOSTRIX POLIO | combined diphtheria, tetanus, acellular pertussis (adsorbed) and inactivated poliomyelitis | J07CA | Parenteral/Suspensions or Emulsions | blank | Within Guidelines |
| 02408872 | BREO ELLIPTA 100/25 MCG/DOSE | fluticasone furoate/vilanterol | R03AK | Pulmonary/Powder | blank | Within Guidelines |
| 02444186 | BREO ELLIPTA 200/25 MCG/DOSE | fluticasone furoate/vilanterol | R03AK | Pulmonary/Powder | blank | Within Guidelines |
| 02212307 | CEFTIN - 25 MG/MILLILITER | cefuroxime axetil | J01DC | Oral Liquid/Powder for suspension | blank | Subj. Investigation |
| 02342227 | CERVARIX | human papillomavirus vaccine (recombinant) | J07BM | Parenteral/Suspensions or Emulsions | blank | Within Guidelines |
| 01916882 | CLAVULIN 25/6.25 MG/MILLILITER | amoxicillin: clavulanic acid | J01CR | Oral Liquid/Suspension | Expired | Does Not Trigger |
| 02238831 | CLAVULIN 40/5.7 MG/MILLILITER | amoxicillin: clavulanic acid | J01CR | Oral Liquid/Suspension | Expired | Does Not Trigger |
| 01916874 | CLAVULIN 50/12.5 MG/MILLILITER | amoxicillin: clavulanic acid | J01CR | Oral Liquid/Suspension | Expired | Within Guidelines |
| 02238830 | CLAVULIN 80/11.4 MG/MILLILITER | amoxicillin: clavulanic acid | J01CR | Oral Liquid/Suspension | Expired | Within Guidelines |
| 01916858 | CLAVULIN 500/125 MG/TABLET | amoxicillin: clavulanic acid | J01CR | Oral Solid/Tablet | Expired | Within Guidelines |
| 02238829 | CLAVULIN 875/125 MG/TABLET | amoxicillin: clavulanic acid | J01CR | Oral Solid/Tablet | Expired | Does Not Trigger |
| 02382822 | CLINDOXYL ADV GEL 10/30 MG/GRAM | clindamycin/benzoyl peroxide | D10AF | Topical/Gel | blank | Within Guidelines |
| 02243158 | CLINDOXYL GEL 10/50 MG/GRAM | clindamycin/benzoyl peroxide | D10AF | Topical/Gel | blank | Subj. Investigation |
| 01919431 | ENGERIX-B | hepatitis b vaccine (recombinant) | J07BC | Parenteral/Suspensions or Emulsions | blank | Does Not Trigger |
| 02487039 | ENGERIX-B | hepatitis b vaccine (recombinant) | J07BC | Parenteral/Suspensions or Emulsions | blank | Subj. Investigation |
| 02296454 | ENGERIX-B PEDIATRIC - 20 MCG/MILLILITER | hepatitis b vaccine (recombinant) | J07BC | Parenteral/Suspensions or Emulsions | blank | Subj. Investigation |
| 02487020 | ENGERIX-B PEDIATRIC - 20 MCG/MILLILITER | hepatitis b vaccine (recombinant) | J07BC | Parenteral/Suspensions or Emulsions | blank | Within Guidelines |
| 02420783 | FLULAVAL TETRA - 15 UNIT/DOSE | quadrivalent influenza vaccine (inactivated, split-virion) | J07BB | Parenteral/Suspensions or Emulsions | blank | Subj. Investigation |
| 02420686 | FLUVIRAL | influenza virus vaccine trivalent (inactivated, split-virion) | J07BB | Parenteral/Suspensions or Emulsions | blank | Subj. Investigation |
| 02187078 | HAVRIX 1440 - 1440 UNIT/MILLILITER | hepatitis a vaccine, inactivated | J07BC | Parenteral/Suspensions or Emulsions | blank | Subj. Investigation |
| 02231056 | HAVRIX 720 JUNIOR - 1440 UNIT/MILLILITER | hepatitis a vaccine, inactivated | J07BC | Parenteral/Suspensions or Emulsions | blank | Subj. Investigation |
| 02239200 | HIBERIX | haemophilus influenzae type b (hib) conjugate vaccine (tetanus protein – conjugate) | J07AG | Parenteral/Powder for solution | blank | Within Guidelines |
| 02230418 | IMITREX - 5 MG/DOSE | sumatriptan hemisulphate | N02CC | Nasal/Spray | blank | Within Guidelines |
| 02230420 | IMITREX - 20 MG/DOSE | sumatriptan hemisulphate | N02CC | Nasal/Spray | blank | Within Guidelines |
| 02212188 | IMITREX - 12 MG/MILLILITER | sumatriptan succinate | N02CC | Parenteral/Solution | blank | Does Not Trigger |
| 02212153 | IMITREX DF - 50 MG/TABLET | sumatriptan succinate | N02CC | Oral Solid/Tablet | blank | Does Not Trigger |
| 02212161 | IMITREX DF - 100 MG/TABLET | sumatriptan succinate | N02CC | Oral Solid/Tablet | blank | Does Not Trigger |
| 02423596 | INCRUSE ELLIPTA - 62.5 MCG/DOSE | umeclidinium bromide | R03BB | Pulmonary/Powder | blank | Within Guidelines |
| 02253852 | INFANRIX HEXA | combined diphtheria and tetanus toxoids, acellular pertussis, hepatitis b (recombinant), inactivated poliomyelitis and adsorbed conjugated haemophilus influenzae type b vaccine | J07CA | Parenteral/Suspensions or Emulsions | blank | Within Guidelines |
| 02241284 | INFANRIX-IPV | combined diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine | J07CA | Parenteral/Suspensions or Emulsions | blank | Within Guidelines |
| 02440709 | MENJUGATE LIQUID | meningococcal group c conjugate vaccine | J07AH | Parenteral/Suspensions or Emulsions | blank | Within Guidelines |
| 02347393 | MENVEO - 72 MCG/DOSE | meningococcal group a, c, w-135, y oligosaccharide, corynebacterium diphtheriae crm-197 protein vaccine | J07AH | Parenteral/Powder for solution | blank | Subj. Investigation |
| 02239208 | PRIORIX | combined measles, mumps and rubella vaccine, live, attenuated | J07BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02297884 | PRIORIX - TETRA | combined measles, mumps, rubella and varicella vaccine, live, attenuated | J07BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02267667 | RABAVERT | rabies vaccine inactivated | J07BG | Parenteral/Powder for solution | Expired | Does Not Trigger |
| 02300591 | ROTARIX | rotavirus vaccine (rix4414 strain), live, oral, attenuated (human) | J07BH | Oral Liquid/Powder for suspension | blank | Within Guidelines |
| 02468425 | SHINGRIX - 50 MCG/DOSE | varicella-zoster virus glycoprotein e antigen | J07BK | Parenteral/Suspensions or Emulsions | blank | Does Not Trigger |
| 00657204 | STIEVA-A CREAM - 0.1 MG/GRAM | tretinoin | D10AD | Topical/Cream | blank | Within Guidelines |
| 00578576 | STIEVA-A CREAM - 0.25 MG/GRAM | tretinoin | D10AD | Topical/Cream | blank | Within Guidelines |
| 00518182 | STIEVA-A CREAM - 0.5 MG/GRAM | tretinoin | D10AD | Topical/Cream | blank | Does Not Trigger |
| 02320541 | SYNFLORIX | pneumococcal conjugate | J07AL | Parenteral/Suspensions or Emulsions | blank | Within Guidelines |
| 02474522 | TRELEGY ELLIPTA 100/62.5/25 MCG/DOSE | fluticasone furoate/umeclidinium/vilanterol | R03AL | Pulmonary/Powder | blank | Within Guidelines |
| 02230578 | TWINRIX 720/20 | combined hepatitis a (inactivated) and hepatitis b (recombinant) vaccine | J07BC | Parenteral/Suspensions or Emulsions | blank | Subj. Investigation |
| 02237548 | TWINRIX JUNIOR 360/10 | combined hepatitis a (inactivated) and hepatitis b (recombinant) vaccine | J07BC | Parenteral/Suspensions or Emulsions | blank | Subj. Investigation |
| 02241047 | VARILRIX | varicella virus vaccine, live, attenuated (oka-strain) | J07BK | Parenteral/Powder for solution | blank | Within Guidelines |
| 02307065 | VOLIBRIS - 5 MG/TABLET | ambrisentan | C02KX | Oral Solid/Tablet | blank | Within Guidelines |
| 02307073 | VOLIBRIS - 10 MG/TABLET | ambrisentan | C02KX | Oral Solid/Tablet | blank | Within Guidelines |
| 02489783 | ZEJULA - 100 MG/CAPSULE | niraparib tosylate | L01XX | Oral Solid/Capsule | Introduced | Subj. Investigation |
| 00886157 | ZOVIRAX - 40 MG/MILLILITER | acyclovir | J05AB | Oral Liquid/Suspension | Expired | Subj. Investigation |
Grifols Canada Ltd.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02189100 | PLASBUMIN-5 - 50 MG/MILLILITER | albumin (human) | B05AA | Parenteral/Solution | blank | Subj. Investigation |
| 02204606 | PROLASTIN - 25 MG/MILLILITER | alpha1-proteinase inhibitor (human) | B02AB | Parenteral/Powder for solution | blank | Within Guidelines |
H
HLS Therapeutics Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02495244 | VASCEPA - 1 G/CAPSULE | icosapent ethyl | C10AX | Oral Solid/Capsule | blank | Does Not Trigger |
Hoffmann-La Roche Limited
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02350092 | ACTEMRA - 20 MG/MILLILITER | tocilizumab | L04AC | Parenteral/Solution | blank | Within Guidelines |
| 02350106 | ACTEMRA - 20 MG/MILLILITER | tocilizumab | L04AC | Parenteral/Solution | blank | Within Guidelines |
| 02350114 | ACTEMRA - 20 MG/MILLILITER | tocilizumab | L04AC | Parenteral/Solution | blank | Within Guidelines |
| 02424770 | ACTEMRA - 162 MG/SYRINGE | tocilizumab | L04AC | Parenteral/Solution | blank | Within Guidelines |
| 02483327 | ACTEMRA - 162 MG/SYRINGE | tocilizumab | L04AC | Parenteral/Solution | blank | Within Guidelines |
| 02225689 | ACTIVASE - 50 MG/VIAL | alteplase | B01AD | Parenteral/Solution | blank | Within Guidelines |
| 02147440 | ACTIVASE - 100 MG/VIAL | alteplase | B01AD | Parenteral/Solution | blank | Within Guidelines |
| 02458136 | ALECENSARO - 150 MG/CAPSULE | alectinib | L01XE | Oral Solid/Capsule | blank | Within Guidelines |
| 02270994 | AVASTIN - 25 MG/MILLILITER | bevacizumab | L01XC | Parenteral/Solution | blank | Within Guidelines |
| 02245859 | CATHFLO - 2 MG/VIAL | alteplase | B01AD | Parenteral/Solution | blank | Within Guidelines |
| 02452340 | COTELLIC - 20 MG/TABLET | cobimetinib fumarate | L01XE | Oral Solid/Tablet | blank | Subj. Investigation |
| 02499681 | ENSPRYNG - 120 MG/MILLILITER | satralizumab | L04AC | Parenteral/Solution | Introduced | Under Review |
| 02409267 | ERIVEDGE - 150 MG/CAPSULE | vismodegib | L01XX | Oral Solid/Capsule | blank | Within Guidelines |
| 02393751 | ESBRIET - 267 MG/CAPSULE | pirfenidone | L04AX | Oral Solid/Capsule | blank | Subj. Investigation |
| 02464489 | ESBRIET - 267 MG/TABLET | pirfenidone | L04AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02464500 | ESBRIET - 801 MG/TABLET | pirfenidone | L04AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02434806 | GAZYVA - 25 MG/MILLILITER | obinutuzumab | L01XC | Parenteral/Solution | blank | Within Guidelines |
| 02479621 | HEMLIBRA - 30 MG/MILLILITER | emicizumab | B02BX | Parenteral/Solution | blank | Within Guidelines |
| 02479648 | HEMLIBRA - 60 MG/VIAL | emicizumab | B02BX | Parenteral/Solution | blank | Within Guidelines |
| 02479656 | HEMLIBRA - 105 MG/VIAL | emicizumab | B02BX | Parenteral/Solution | blank | Within Guidelines |
| 02479664 | HEMLIBRA - 150 MG/MILLILITER | emicizumab | B02BX | Parenteral/Solution | blank | Subj. Investigation |
| 02240692 | HERCEPTIN - 440 MG/VIAL | trastuzumab | L01XC | Parenteral/Solution | blank | Subj. Investigation |
| 02480697 | HERCEPTIN SC - 600 MG/VIAL | trastuzumab | L01XC | Parenteral/Solution | blank | Subj. Investigation |
| 02216965 | INVIRASE - 200 MG/CAPSULE | saquinavir mesylate | J05AE | Oral Solid/Capsule | blank | Within Guidelines |
| 02279320 | INVIRASE - 500 MG/TABLET | saquinavir mesylate | J05AE | Oral Solid/Tablet | blank | Within Guidelines |
| 02412365 | KADCYLA - 20 MG/MILLILITER | trastuzumab emtansine | L01XC | Parenteral/Powder for solution | blank | Within Guidelines |
| 02473224 | KADCYLA - 20 MG/MILLILITER | trastuzumab emtansine | L01XC | Parenteral/Powder for solution | blank | Within Guidelines |
| 02467224 | OCREVUS - 30 MG/MILLILITER | ocrelizumab | L04AA | Parenteral/Solution | blank | Subj. Investigation |
| 02405016 | PERJETA - 420 MG/VIAL | pertuzumab | L01XC | Parenteral/Solution | blank | Within Guidelines |
| 02405024 | PERJETA-HERCEPTIN COMBO PACK 420/440 MG/VIAL | pertuzumab/trastuzumab | L01XC | Parenteral/Other | blank | Within Guidelines |
| 02499614 | POLIVY - 140 MG/VIAL | polatuzumab vedotin | L01XC | Parenteral/Powder for solution | Introduced | Under Review |
| 02241927 | RITUXAN - 10 MG/MILLILITER | rituximab | L01XC | Parenteral/Solution | blank | Within Guidelines |
| 02457350 | RITUXAN SC - 120 MG/MILLILITER | rituximab | L01XC | Parenteral/Solution | blank | Within Guidelines |
| 02473976 | RITUXAN SC - 120 MG/MILLILITER | rituximab | L01XC | Parenteral/Solution | blank | Within Guidelines |
| 02495015 | ROZLYTREK - 200 MG/CAPSULE | entrectinib | L01XE | Oral Solid/Capsule | Introduced | Within Guidelines |
| 02381842 | TAMIFLU (SEASONAL) - 6 MG/MILLILITER | oseltamivir phosphate | J05AH | Oral Liquid/Powder for suspension | blank | Does Not Trigger |
| 02304848 | TAMIFLU (SEASONAL) - 30 MG/CAPSULE | oseltamivir phosphate | J05AH | Oral Solid/Capsule | blank | Does Not Trigger |
| 02304856 | TAMIFLU (SEASONAL) - 45 MG/CAPSULE | oseltamivir phosphate | J05AH | Oral Solid/Capsule | blank | Does Not Trigger |
| 02241472 | TAMIFLU (SEASONAL) - 75 MG/CAPSULE | oseltamivir phosphate | J05AH | Oral Solid/Capsule | blank | Subj. Investigation |
| 02269007 | TARCEVA - 25 MG/TABLET | erlotinib hydrochloride | L01XX | Oral Solid/Tablet | blank | Does Not Trigger |
| 02269015 | TARCEVA - 100 MG/TABLET | erlotinib hydrochloride | L01XX | Oral Solid/Tablet | blank | Does Not Trigger |
| 02269023 | TARCEVA - 150 MG/TABLET | erlotinib hydrochloride | L01XX | Oral Solid/Tablet | blank | Within Guidelines |
| 02462990 | TECENTRIQ - 60 MG/MILLILITER | atezolizumab | L01XC | Parenteral/Solution | Expired | Subj. Investigation |
| 02492393 | TECENTRIQ - 60 MG/MILLILITER | atezolizumab | L01XC | Parenteral/Solution | Expired | Subj. Investigation |
| 02244826 | TNKASE - 50 MG/VIAL | tenecteplase | B01AD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02306085 | VALCYTE - 50 MG/MILLILITER | valganciclovir hydrochloride | J05AB | Oral Liquid/Powder for solution | blank | Within Guidelines |
| 02245777 | VALCYTE - 450 MG/TABLET | valganciclovir hydrochloride | J05AB | Oral Solid/Tablet | blank | Does Not Trigger |
| 02238453 | XELODA - 150 MG/TABLET | capecitabine | L01BC | Oral Solid/Tablet | blank | Within Guidelines |
| 02238454 | XELODA - 500 MG/TABLET | capecitabine | L01BC | Oral Solid/Tablet | blank | Within Guidelines |
| 02380242 | ZELBORAF - 240 MG/TABLET | vemurafenib | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
Horizon Pharma PLC
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| blank | ACTIMMUNE - 100 MCG/VIAL | interferon gamma 1b | L03AB | Parenteral/Solution | blank | Does Not Trigger |
| 02464705 | PROCYSBI - 25 MG/CAPSULE | cysteamine bitartrate | A16AA | Oral Solid/Modified release capsules | blank | Notice of Hearing |
| 02464713 | PROCYSBI - 75 MG/CAPSULE | cysteamine bitartrate | A16AA | Oral Solid/Modified release capsules | blank | Notice of Hearing |
| 02442302 | QUINSAIR - 100 MG/MILLILITER | levofloxacin | J01MA | Pulmonary/Solution | blank | Within Guidelines |
I
Indivior Canada Ltd.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02483084 | SUBLOCADE - 100 MG/SYRINGE | buprenorphine | N07BC | Parenteral/Solution (extended release) | blank | Subj. Investigation |
| 02483092 | SUBLOCADE - 300 MG/SYRINGE | buprenorphine | N07BC | Parenteral/Solution (extended release) | blank | Subj. Investigation |
| 02502313 | SUBOXONE 2/0.5 MG/FILM | buprenorphine/naloxone | N07BC | Oral Solid/Other | blank | Subj. Investigation |
| 02502348 | SUBOXONE 8/2 MG/FILM | buprenorphine/naloxone | N07BC | Oral Solid/Other | blank | Subj. Investigation |
| 02502356 | SUBOXONE 12/3 MG/FILM | buprenorphine/naloxone | N07BC | Oral Solid/Other | blank | Subj. Investigation |
Intega Skin Sciences Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02398028 | PLIAGLIS 70/70 MG/GRAM | lidocaine/tetracaine | N01BB | Topical/Cream | Expired | Does Not Trigger |
Intercept Pharmaceuticals Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02463121 | OCALIVA - 5 MG/TABLET | obeticholic acid | A05AA | Oral Solid/Tablet | blank | Within Guidelines |
| 02463148 | OCALIVA - 10 MG/TABLET | obeticholic acid | A05AA | Oral Solid/Tablet | blank | Within Guidelines |
IPSEN Biopharmaceuticals Canada Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02480824 | CABOMETYX - 20 MG/TABLET | cabozantinib | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02480832 | CABOMETYX - 40 MG/TABLET | cabozantinib | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02480840 | CABOMETYX - 60 MG/TABLET | cabozantinib | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02387735 | DYSPORT AESTHETIC - 300 UNIT/VIAL | abobotulinumtoxina | M03AX | Parenteral/Powder for solution | blank | Within Guidelines |
| 02460203 | DYSPORT THERAPEUTIC - 300 UNIT/VIAL | abobotulinumtoxina | M03AX | Parenteral/Powder for solution | blank | Subj. Investigation |
| 02456117 | DYSPORT THERAPEUTIC - 500 UNIT/VIAL | abobotulinumtoxina | M03AX | Parenteral/Powder for solution | blank | Subj. Investigation |
| 02509733 | INCRELEX - 10 MG/MILLILITER | mecasermin | H01AC | Parenteral/Solution | blank | Subj. Investigation |
| 02283395 | SOMATULINE AUTOGEL - 60 MG/SYRINGE | lanreotide | H01CB | Parenteral/Solution | blank | Within Guidelines |
| 02283409 | SOMATULINE AUTOGEL - 90 MG/SYRINGE | lanreotide | H01CB | Parenteral/Solution | blank | Does Not Trigger |
| 02283417 | SOMATULINE AUTOGEL - 120 MG/SYRINGE | lanreotide | H01CB | Parenteral/Solution | blank | Within Guidelines |
| 02481553 | XERMELO - 250 MG/TABLET | telotristat ethyl | A16AX | Oral Solid/Tablet | blank | Within Guidelines |
J
Janssen Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02493217 | BALVERSA - 3 MG/TABLET | erdafitinib | L01XE | Oral Solid/Tablet | Introduced | Within Guidelines |
| 02493225 | BALVERSA - 4 MG/TABLET | erdafitinib | L01XE | Oral Solid/Tablet | Introduced | Within Guidelines |
| 02493233 | BALVERSA - 5 MG/TABLET | erdafitinib | L01XE | Oral Solid/Tablet | Introduced | Within Guidelines |
| 02238389 | CAELYX - 2 MG/MILLILITER | doxorubicin hydrochloride | L01DB | Parenteral/Solution | Expired | Within Guidelines |
| 02397447 | CARIPUL - 0.5 MG/VIAL | epoprostenol sodium | B01AC | Parenteral/Powder for solution | blank | Does Not Trigger |
| 02397455 | CARIPUL - 1.5 MG/VIAL | epoprostenol sodium | B01AC | Parenteral/Powder for solution | blank | Within Guidelines |
| 02455951 | DARZALEX - 100 MG/VIAL | daratumumab | L01XC | Parenteral/Solution | blank | Within Guidelines |
| 02455978 | DARZALEX - 400 MG/VIAL | daratumumab | L01XC | Parenteral/Solution | blank | Within Guidelines |
| 02502712 | DARZALEX SC - 1800 MG/VIAL | daratumumab | L01CX | Parenteral/Solution | Introduced | Under Review |
| 02370603 | EDURANT - 25 MG/TABLET | rilpivirine hydrochloride | J05AG | Oral Solid/Tablet | blank | Does Not Trigger |
| 02231583 | EPREX - 1000 UNIT/SYRINGE | epoetin alfa | B03XA | Parenteral/Solution | blank | Within Guidelines |
| 02231584 | EPREX - 2000 UNIT/SYRINGE | epoetin alfa | B03XA | Parenteral/Solution | blank | Within Guidelines |
| 02231585 | EPREX - 3000 UNIT/SYRINGE | epoetin alfa | B03XA | Parenteral/Solution | blank | Within Guidelines |
| 02231586 | EPREX - 4000 UNIT/SYRINGE | epoetin alfa | B03XA | Parenteral/Solution | blank | Within Guidelines |
| 02243400 | EPREX - 5000 UNIT/SYRINGE | epoetin alfa | B03XA | Parenteral/Solution | blank | Within Guidelines |
| 02243401 | EPREX - 6000 UNIT/SYRINGE | epoetin alfa | B03XA | Parenteral/Solution | blank | Within Guidelines |
| 02243403 | EPREX - 8000 UNIT/SYRINGE | epoetin alfa | B03XA | Parenteral/Solution | blank | Within Guidelines |
| 02231587 | EPREX - 10000 UNIT/MILLILITER | epoetin alfa | B03XA | Parenteral/Solution | blank | Within Guidelines |
| 02243239 | EPREX - 20000 UNIT/SYRINGE | epoetin alfa | B03XA | Parenteral/Solution | blank | Within Guidelines |
| 02288680 | EPREX - 30000 UNIT/SYRINGE | epoetin alfa | B03XA | Parenteral/Solution | blank | Within Guidelines |
| 02240722 | EPREX - 40000 UNIT/MILLILITER | epoetin alfa | B03XA | Parenteral/Solution | blank | Within Guidelines |
| 02478374 | ERLEADA - 60 MG/TABLET | apalutamide | L02BB | Oral Solid/Tablet | blank | Within Guidelines |
| 02434407 | IMBRUVICA - 140 MG/CAPSULE | ibrutinib | L01XE | Oral Solid/Capsule | blank | Within Guidelines |
| 02306778 | INTELENCE - 100 MG/TABLET | etravirine | J05AG | Oral Solid/Tablet | blank | Within Guidelines |
| 02375931 | INTELENCE - 200 MG/TABLET | etravirine | J05AG | Oral Solid/Tablet | blank | Does Not Trigger |
| 02300273 | INVEGA - 3 MG/TABLET | paliperidone | N05AX | Oral Solid/Modified release tablets | blank | Within Guidelines |
| 02300281 | INVEGA - 6 MG/TABLET | paliperidone | N05AX | Oral Solid/Modified release tablets | blank | Does Not Trigger |
| 02300303 | INVEGA - 9 MG/TABLET | paliperidone | N05AX | Oral Solid/Modified release tablets | blank | Does Not Trigger |
| 02354217 | INVEGA SUSTENNA - 50 MG/SYRINGE | paliperidone | N05AX | Parenteral/Modified release injections | blank | Within Guidelines |
| 02354225 | INVEGA SUSTENNA - 75 MG/SYRINGE | paliperidone | N05AX | Parenteral/Modified release injections | blank | Within Guidelines |
| 02354233 | INVEGA SUSTENNA - 100 MG/SYRINGE | paliperidone | N05AX | Parenteral/Modified release injections | blank | Within Guidelines |
| 02354241 | INVEGA SUSTENNA - 150 MG/SYRINGE | paliperidone | N05AX | Parenteral/Modified release injections | blank | Within Guidelines |
| 02455943 | INVEGA TRINZA - 175 MG/SYRINGE | paliperidone palmitate | N05AX | Parenteral/Suspension (extended release) | blank | Within Guidelines |
| 02455986 | INVEGA TRINZA - 263 MG/SYRINGE | paliperidone palmitate | N05AX | Parenteral/Suspension (extended release) | blank | Within Guidelines |
| 02455994 | INVEGA TRINZA - 350 MG/SYRINGE | paliperidone palmitate | N05AX | Parenteral/Suspension (extended release) | blank | Within Guidelines |
| 02456001 | INVEGA TRINZA - 525 MG/SYRINGE | paliperidone palmitate | N05AX | Parenteral/Suspension (extended release) | blank | Within Guidelines |
| 02455404 | INVOKAMET 50/500 MG/TABLET | canagliflozin/metformin hydrochloride | A10BD | Oral Solid/Tablet | blank | Within Guidelines |
| 02455420 | INVOKAMET 50/1000 MG/TABLET | canagliflozin/metformin hydrochloride | A10BD | Oral Solid/Tablet | blank | Within Guidelines |
| 02455439 | INVOKAMET 150/500 MG/TABLET | canagliflozin/metformin hydrochloride | A10BD | Oral Solid/Tablet | blank | Does Not Trigger |
| 02455455 | INVOKAMET 150/1000 MG/TABLET | canagliflozin/metformin hydrochloride | A10BD | Oral Solid/Tablet | blank | Within Guidelines |
| 02425483 | INVOKANA - 100 MG/TABLET | canagliflozin | A10BX | Oral Solid/Tablet | blank | Within Guidelines |
| 02425491 | INVOKANA - 300 MG/TABLET | canagliflozin | A10BX | Oral Solid/Tablet | blank | Within Guidelines |
| 02415690 | OPSUMIT - 10 MG/TABLET | macitentan | C02KX | Oral Solid/Tablet | blank | Within Guidelines |
| 02426501 | PREZCOBIX 800/150 MG/TABLET | darunavir/cobicistat | J05AR | Oral Solid/Tablet | blank | Within Guidelines |
| 02338432 | PREZISTA - 75 MG/TABLET | darunavir ethanolate | J05AE | Oral Solid/Tablet | blank | Does Not Trigger |
| 02369753 | PREZISTA - 150 MG/TABLET | darunavir ethanolate | J05AE | Oral Solid/Tablet | blank | Does Not Trigger |
| 02324024 | PREZISTA - 600 MG/TABLET | darunavir ethanolate | J05AE | Oral Solid/Tablet | blank | Within Guidelines |
| 02393050 | PREZISTA - 800 MG/TABLET | darunavir ethanolate | J05AE | Oral Solid/Tablet | blank | Within Guidelines |
| 02377012 | RESOTRAN - 1 MG/TABLET | prucalopride succinate | A03AE | Oral Solid/Tablet | Expired | Does Not Trigger |
| 02377020 | RESOTRAN - 2 MG/TABLET | prucalopride succinate | A03AE | Oral Solid/Tablet | Expired | Does Not Trigger |
| 02236950 | RISPERDAL - 1 MG/MILLILITER | risperidone | N05AX | Oral Liquid/Solution | blank | Within Guidelines |
| 02298465 | RISPERDAL CONSTA - 12.5 MG/VIAL | risperidone | N05AX | Parenteral/Modified release injections | blank | Within Guidelines |
| 02255707 | RISPERDAL CONSTA - 25 MG/VIAL | risperidone | N05AX | Parenteral/Modified release injections | blank | Within Guidelines |
| 02255723 | RISPERDAL CONSTA - 37.5 MG/VIAL | risperidone | N05AX | Parenteral/Modified release injections | blank | Within Guidelines |
| 02255758 | RISPERDAL CONSTA - 50 MG/VIAL | risperidone | N05AX | Parenteral/Modified release injections | blank | Within Guidelines |
| 02324776 | SIMPONI - 50 MG/SYRINGE | golimumab | L04AB | Parenteral/Solution | blank | Within Guidelines |
| 02324784 | SIMPONI - 50 MG/SYRINGE | golimumab | L04AB | Parenteral/Solution | blank | Within Guidelines |
| 02417472 | SIMPONI - 50 MG/VIAL | golimumab | L04AB | Parenteral/Solution | blank | Within Guidelines |
| 02413183 | SIMPONI - 100 MG/MILLILITER | golimumab | L04AB | Parenteral/Solution | blank | Within Guidelines |
| 02413175 | SIMPONI - 100 MG/SYRINGE | golimumab | L04AB | Parenteral/Solution | blank | Within Guidelines |
| 02320673 | STELARA - 45 MG/VIAL | ustekinumab | L04AC | Parenteral/Solution | blank | Within Guidelines |
| 02320681 | STELARA - 90 MG/VIAL | ustekinumab | L04AC | Parenteral/Solution | blank | Within Guidelines |
| 02459671 | STELARA - 130 MG/VIAL | ustekinumab | L04AC | Parenteral/Solution | blank | Within Guidelines |
| 02435128 | SYLVANT - 100 MG/VIAL | siltuximab | L04AC | Parenteral/Powder for solution | blank | Within Guidelines |
| 02435136 | SYLVANT - 400 MG/VIAL | siltuximab | L04AC | Parenteral/Powder for solution | blank | Within Guidelines |
| 02473720 | SYMTUZA 800/150/200/10 | darunavir/cobicistat/emtricitabine/tenofovir alafenamide | J05AR | Oral Solid/Tablet | blank | Within Guidelines |
| 02337630 | TOCTINO - 10 MG/CAPSULE | alitretinoin | D11AX | Oral Solid/Capsule | blank | Within Guidelines |
| 02337649 | TOCTINO - 30 MG/CAPSULE | alitretinoin | D11AX | Oral Solid/Capsule | blank | Within Guidelines |
| 02244981 | TRACLEER - 62.5 MG/TABLET | bosentan monohydrate | C02KX | Oral Solid/Tablet | blank | Within Guidelines |
| 02244982 | TRACLEER - 125 MG/TABLET | bosentan monohydrate | C02KX | Oral Solid/Tablet | blank | Within Guidelines |
| 02469758 | TREMFYA - 100 MG/MILLILITER | guselkumab | L04AC | Parenteral/Solution | blank | Within Guidelines |
| 02487314 | TREMFYA ONE-PRESS - 100 MG/MILLILITER | guselkumab | L04AC | Parenteral/Solution | blank | Within Guidelines |
| 02451158 | UPTRAVI - 200 MCG/TABLET | selexipag | B01AC | Oral Solid/Tablet | blank | Subj. Investigation |
| 02451166 | UPTRAVI - 400 MCG/TABLET | selexipag | B01AC | Oral Solid/Tablet | blank | Within Guidelines |
| 02451174 | UPTRAVI - 600 MCG/TABLET | selexipag | B01AC | Oral Solid/Tablet | blank | Does Not Trigger |
| 02451182 | UPTRAVI - 800 MCG/TABLET | selexipag | B01AC | Oral Solid/Tablet | blank | Within Guidelines |
| 02451190 | UPTRAVI - 1000 MCG/TABLET | selexipag | B01AC | Oral Solid/Tablet | blank | Within Guidelines |
| 02451204 | UPTRAVI - 1200 MCG/TABLET | selexipag | B01AC | Oral Solid/Tablet | blank | Within Guidelines |
| 02451212 | UPTRAVI - 1400 MCG/TABLET | selexipag | B01AC | Oral Solid/Tablet | blank | Within Guidelines |
| 02451220 | UPTRAVI - 1600 MCG/TABLET | selexipag | B01AC | Oral Solid/Tablet | blank | Within Guidelines |
| 02262452 | VELCADE - 3.5 MG/VIAL | bortezomib | L01XX | Parenteral/Powder for solution | blank | Within Guidelines |
| 02250519 | ZAVESCA - 100 MG/CAPSULE | miglustat | A16AX | Oral Solid/Capsule | Expired | Within Guidelines |
| 02371065 | ZYTIGA - 250 MG/TABLET | abiraterone acetate | L02BX | Oral Solid/Tablet | blank | Within Guidelines |
| 02457113 | ZYTIGA - 500 MG/TABLET | abiraterone acetate | L02BX | Oral Solid/Tablet | blank | Within Guidelines |
Jazz Pharmaceuticals, PLC
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02465981 | DEFITELIO - 200 MG/VIAL | defibrotide sodium | B01AX | Parenteral/Solution | blank | Within Guidelines |
| 02268272 | XYREM - 500 MG/MILLILITER | sodium oxybate | N07XX | Oral Liquid/Solution | blank | Within Guidelines |
Johnson & Johnson Medical Products
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02348497 | EVICEL | thrombin (human)/fibrinogen (human) | B02BC | Topical/Liquid | blank | Within Guidelines |
K
Knight Therapeutics Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02442167 | MOVANTIK - 12.5 MG/TAB | naloxegol oxalate | A06AH | Oral Solid/Tablet | blank | Within Guidelines |
| 02442175 | MOVANTIK - 25 MG/TAB | naloxegol oxalate | A06AH | Oral Solid/Tablet | blank | Within Guidelines |
| 02490536 | NERLYNX - 40 MG/TABLET | neratinib | L01XE | Oral Solid/Tablet | blank | Subj. Investigation |
| 02474921 | PROBUPHINE - 80 MG/IMPLANT | buprenorphine hydrochloride | N07BC | Parenteral/Implant | blank | Within Guidelines |
| 02240000 | TRELSTAR - 3.75 MG/VIAL | triptorelin pamoate | L02AE | Parenteral/Powder for solution | Expired | Within Guidelines |
| 02243856 | TRELSTAR - 11.25 MG/VIAL | triptorelin pamoate | L02AE | Parenteral/Powder for solution | Expired | Within Guidelines |
| 02412322 | TRELSTAR - 22.5 MG/VIAL | triptorelin pamoate | L02AE | Parenteral/Powder for solution | Expired | Within Guidelines |
L
Labtician Théa
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02456230 | MONOPROST - 0.2 ML/DOSE | latanoprost | S01EE | Ophthalmic/Solution | blank | Subj. Investigation |
Lantheus Mi Canada Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02243173 | DEFINITY - 150 MCL/MILLILITRE | perflutren | V08DA | Parenteral/Suspensions or Emulsions | blank | Within Guidelines |
Leo Pharma Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02244126 | DOVOBET 0.05/0.5 MG/GRAM | calcipotriol/betamethasone dipropionate | D05AX | Topical/Ointment | Expired | Does Not Trigger |
| 02319012 | DOVOBET GEL 0.05/0.5 MG/GRAM | calcipotriol/betamethasone dipropionate | D05AX | Topical/Gel | blank | Within Guidelines |
| 02457393 | ENSTILAR - 0.55 MG/GRAM | calcipotriol/betamethasone dipropionate | D05AX | Topical/Aerosol (foam) | blank | Does Not Trigger |
Lundbeck Canada Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02239607 | CELEXA - 20 MG/TABLET | citalopram hydrobromide | N06AB | Oral Solid/Tablet | blank | Within Guidelines |
| 02239608 | CELEXA - 40 MG/TABLET | citalopram hydrobromide | N06AB | Oral Solid/Tablet | blank | Within Guidelines |
| 02263238 | CIPRALEX - 10 MG/TABLET | escitalopram oxalate | N06AB | Oral Solid/Tablet | Expired | Within Guidelines |
| 02263254 | CIPRALEX - 20 MG/TABLET | escitalopram oxalate | N06AB | Oral Solid/Tablet | Expired | Within Guidelines |
| 02432919 | TRINTELLIX - 5 MG/TABLET | vortioxetine hydrobromide | N06AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02432927 | TRINTELLIX - 10 MG/TABLET | vortioxetine hydrobromide | N06AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02432943 | TRINTELLIX - 20 MG/TABLET | vortioxetine hydrobromide | N06AX | Oral Solid/Tablet | blank | Within Guidelines |
Lupin Pharma Canada Limited
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02410702 | ZAXINE - 550 MG/TABLET | rifaximin | A07AA | Oral Solid/Tablet | blank | Within Guidelines |
M
Medexus Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02454831 | METOJECT SUBCUTANEOUS - 10 MG/SYRINGE | methotrexate sodium | L04AX | Parenteral/Solution | blank | Within Guidelines |
| 02454750 | METOJECT SUBCUTANEOUS - 12.5 MG/SYRINGE | methotrexate sodium | L04AX | Parenteral/Solution | blank | Within Guidelines |
| 02454858 | METOJECT SUBCUTANEOUS - 15 MG/SYRINGE | methotrexate sodium | L04AX | Parenteral/Solution | blank | Within Guidelines |
| 02454769 | METOJECT SUBCUTANEOUS - 17.5 MG/SYRINGE | methotrexate sodium | L04AX | Parenteral/Solution | blank | Within Guidelines |
| 02454866 | METOJECT SUBCUTANEOUS - 20 MG/SYRINGE | methotrexate sodium | L04AX | Parenteral/Solution | blank | Subj. Investigation |
| 02454777 | METOJECT SUBCUTANEOUS - 22.5 MG/SYRINGE | methotrexate sodium | L04AX | Parenteral/Solution | blank | Within Guidelines |
| 02454874 | METOJECT SUBCUTANEOUS - 25 MG/SYRINGE | methotrexate sodium | L04AX | Parenteral/Solution | blank | Subj. Investigation |
Merck Canada Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02438690 | ASMANEX TWISTHALER - 100 MCG/DOSE | mometasone furoate | R03BA | Pulmonary/Powder | Expired | Does Not Trigger |
| 02243595 | ASMANEX TWISTHALER - 200 MCG/DOSE | mometasone furoate | R03BA | Pulmonary/Powder | Expired | Within Guidelines |
| 02243596 | ASMANEX TWISTHALER - 400 MCG/DOSE | mometasone furoate | R03BA | Pulmonary/Powder | Expired | Within Guidelines |
| 02483513 | BELSOMRA - 10 MG/TABLET | suvorexant | N05CM | Oral Solid/Tablet | blank | Within Guidelines |
| 02483521 | BELSOMRA - 15 MG/TABLET | suvorexant | N05CM | Oral Solid/Tablet | blank | Within Guidelines |
| 02483548 | BELSOMRA - 20 MG/TABLET | suvorexant | N05CM | Oral Solid/Tablet | blank | Within Guidelines |
| 02451816 | BRIDION - 100 MG/MILLILITER | sugammadex | V03AB | Parenteral/Solution | Expired | Within Guidelines |
| 02482592 | DELSTRIGO 100/300/300 MG/TABLET | doravirine/lamivudine/tenofovir disoproxil fumarate | J05AR | Oral Solid/Tablet | blank | Within Guidelines |
| 02387174 | DIFICID - 200 MG/TABLET | fidaxomicin | A07AA | Oral Solid/Tablet | blank | Within Guidelines |
| 02247521 | EZETROL - 10 MG/TABLET | ezetimibe | C10AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02437058 | GARDASIL 9 | human papillomavirus 9-valent vaccine recombinant | J07BM | Parenteral/Suspensions or Emulsions | blank | Within Guidelines |
| 02240351 | INTEGRILIN - 0.75 MG/MILLILITER | eptifibatide | B01AC | Parenteral/Solution | blank | Does Not Trigger |
| 02240352 | INTEGRILIN - 2 MG/MILLILITER | eptifibatide | B01AC | Parenteral/Solution | blank | Subj. Investigation |
| 02238674 | INTRON-A - 6000000 UNIT/MILLILITER | interferon alfa-2b | L03AB | Parenteral/Solution | blank | Subj. Investigation |
| 02238675 | INTRON-A - 10000000 UNIT/MILLILITER | interferon alfa-2b | L03AB | Parenteral/Solution | blank | Within Guidelines |
| 02223406 | INTRON-A - 10000000 UNIT/VIAL | interferon alfa-2b | L03AB | Parenteral/Powder for solution | blank | Within Guidelines |
| 02240694 | INTRON-A PEN HSA FREE - 25000000 UNIT/MILLILITER | interferon alfa-2b | L03AB | Parenteral/Solution | Expired | Subj. Investigation |
| 02247437 | INVANZ - 1000 MG/VIAL | ertapenem sodium | J01DH | Parenteral/Powder for solution | blank | Within Guidelines |
| 02392429 | ISENTRESS - 25 MG/TABLET | raltegravir potassium | J05AX | Oral Solid/Tablet | blank | Does Not Trigger |
| 02392437 | ISENTRESS - 100 MG/TABLET | raltegravir potassium | J05AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02301881 | ISENTRESS - 400 MG/TABLET | raltegravir potassium | J05AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02465337 | ISENTRESS HD - 600 MG/TABLET | raltegravir potassium | J05AX | Oral Solid/Tablet | blank | Subj. Investigation |
| 02333856 | JANUMET 50/500 MG/TABLET | sitagliptin phosphate monohydrate/metformin hydrochloride | A10BD | Oral Solid/Tablet | blank | Subj. Investigation |
| 02333864 | JANUMET 50/850 MG/TABLET | sitagliptin phosphate monohydrate/metformin hydrochloride | A10BD | Oral Solid/Tablet | blank | Subj. Investigation |
| 02333872 | JANUMET 50/1000 MG/TABLET | sitagliptin phosphate monohydrate/metformin hydrochloride | A10BD | Oral Solid/Tablet | blank | Subj. Investigation |
| 02416786 | JANUMET XR 50/500 MG/TABLET | sitagliptin phosphate monohydrate/metformin hydrochloride | A10BD | Oral Solid/Modified release tablets | blank | Subj. Investigation |
| 02416794 | JANUMET XR 50/1000 MG/TABLET | sitagliptin phosphate monohydrate/metformin hydrochloride | A10BD | Oral Solid/Modified release tablets | blank | Within Guidelines |
| 02416808 | JANUMET XR 100/1000 MG/TABLET | sitagliptin phosphate monohydrate/metformin hydrochloride | A10BD | Oral Solid/Modified release tablets | blank | Subj. Investigation |
| 02388839 | JANUVIA - 25 MG/TABLET | sitagliptin phosphate monohydrate | A10BH | Oral Solid/Tablet | blank | Within Guidelines |
| 02388847 | JANUVIA - 50 MG/TABLET | sitagliptin phosphate monohydrate | A10BH | Oral Solid/Tablet | blank | Within Guidelines |
| 02303922 | JANUVIA - 100 MG/TABLET | sitagliptin phosphate monohydrate | A10BH | Oral Solid/Tablet | blank | Within Guidelines |
| 02441152 | KEYTRUDA - 50 MG/VIAL | pembrolizumab | L01XC | Parenteral/Powder for solution | blank | Within Guidelines |
| 02456869 | KEYTRUDA - 100 MG/VIAL | pembrolizumab | L01XC | Parenteral/Solution | blank | Within Guidelines |
| 02481545 | PIFELTRO - 100 MG/TABLET | doravirine | J05AG | Oral Solid/Tablet | blank | Within Guidelines |
| 02293404 | POSANOL - 40 MG/MILLILITER | posaconazole | J02AC | Oral Liquid/Suspension | blank | Within Guidelines |
| 02424622 | POSANOL - 100 MG/TABLET | posaconazole | J02AC | Oral Solid/Tablet | blank | Within Guidelines |
| 02432676 | POSANOL - 300 MG/VIAL | posaconazole | J02AC | Parenteral/Solution | blank | Within Guidelines |
| 02469375 | PREVYMIS - 240 MG/TABLET | letermovir | J05AX | Oral Solid/Tablet | blank | Subj. Investigation |
| 02469383 | PREVYMIS - 480 MG/TABLET | letermovir | J05AX | Oral Solid/Tablet | blank | Subj. Investigation |
| 02469367 | PREVYMIS - 240 MG/VIAL | letermovir | J05AX | Parenteral/Solution | blank | Subj. Investigation |
| 02469405 | PREVYMIS - 480 MG/VIAL | letermovir | J05AX | Parenteral/Solution | blank | Subj. Investigation |
| 02374803 | SAPHRIS - 5 MG/TABLET | asenapine maleate | N05AH | Dental - Sublingual Buccal/Sublingual tablets | blank | Within Guidelines |
| 02374811 | SAPHRIS - 10 MG/TABLET | asenapine maleate | N05AH | Dental - Sublingual Buccal/Sublingual tablets | blank | Does Not Trigger |
| 02476215 | SEGLUROMET 2.5/500 MG/TABLET | ertugliflozin/metformin hydrochloride | A10BD | Oral Solid/Tablet | blank | Within Guidelines |
| 02476223 | SEGLUROMET 2.5/1000 MG/TABLET | ertugliflozin/metformin hydrochloride | A10BD | Oral Solid/Tablet | blank | Within Guidelines |
| 02476231 | SEGLUROMET 7.5/500 MG/TABLET | ertugliflozin/metformin hydrochloride | A10BD | Oral Solid/Tablet | blank | Within Guidelines |
| 02476258 | SEGLUROMET 7.5/1000 MG/TABLET | ertugliflozin/metformin hydrochloride | A10BD | Oral Solid/Tablet | blank | Within Guidelines |
| 02247997 | SINGULAIR - 4 MG/POUCH | montelukast sodium | R03DC | Oral Solid/Effervescent granules | blank | Within Guidelines |
| 02475510 | STEGLATRO - 5 MG/TABLET | ertugliflozin | A10BK | Oral Solid/Tablet | blank | Does Not Trigger |
| 02475529 | STEGLATRO - 15 MG/TABLET | ertugliflozin | A10BK | Oral Solid/Tablet | blank | Within Guidelines |
| 02475901 | STEGLUJAN 5/100 MG/TABLET | ertugliflozin/sitagliptin | A10BD | Oral Solid/Tablet | blank | Within Guidelines |
| 02475928 | STEGLUJAN 15/100 MG/TABLET | ertugliflozin/sitagliptin | A10BD | Oral Solid/Tablet | blank | Within Guidelines |
| 02361752 | ZENHALE 100/5 MG/DOSE | mometasone furoate/formoterol fumarate dihydrate | R03AK | Pulmonary/Metered dose preparations | Expired | Within Guidelines |
| 02361760 | ZENHALE 200/5 MG/DOSE | mometasone furoate/formoterol fumarate dihydrate | R03AK | Pulmonary/Metered dose preparations | Expired | Subj. Investigation |
| 02451131 | ZEPATIER 50/100 MG/TABLET | elbasvir/grazoprevir | J05AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02327619 | ZOLINZA - 100 MG/CAPSULE | vorinostat | L01XX | Oral Solid/Capsule | blank | Within Guidelines |
Merz Pharma Canada Ltd.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02371081 | XEOMIN - 50 UNIT/VIAL | incobotulinumtoxina | M03AX | Parenteral/Powder for solution | blank | Within Guidelines |
| 02324032 | XEOMIN - 100 UNIT/VIAL | incobotulinumtoxina | M03AX | Parenteral/Powder for solution | blank | Within Guidelines |
| 02383489 | XEOMIN COSMETIC - 100 UNIT/VIAL | incobotulinumtoxina | M03AX | Parenteral/Powder for solution | blank | Within Guidelines |
Mitsubishi Tanabe Pharma Canada.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02475472 | RADICAVA - 30 MG/DOSE | edaravone | N07XX | Parenteral/Solution | Expired | Under Review |
N
Noden Pharma Dac
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02302063 | RASILEZ - 150 MG/TABLET | aliskiren fumarate | C09XA | Oral Solid/Tablet | blank | Within Guidelines |
| 02302071 | RASILEZ - 300 MG/TABLET | aliskiren fumarate | C09XA | Oral Solid/Tablet | blank | Within Guidelines |
| 02332728 | RASILEZ HCT 150/12.5 MG/TABLET | aliskiren fumarate/hydrochlorothiazide | C09XA | Oral Solid/Tablet | blank | Within Guidelines |
| 02332736 | RASILEZ HCT 150/25 MG/TABLET | aliskiren fumarate/hydrochlorothiazide | C09XA | Oral Solid/Tablet | blank | Within Guidelines |
| 02332744 | RASILEZ HCT 300/12.5 MG/TABLET | aliskiren fumarate/hydrochlorothiazide | C09XA | Oral Solid/Tablet | blank | Within Guidelines |
| 02332752 | RASILEZ HCT 300/25 MG/TABLET | aliskiren fumarate/hydrochlorothiazide | C09XA | Oral Solid/Tablet | blank | Within Guidelines |
Novartis Pharmaceuticals Canada Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02269198 | ACLASTA - 5 MG/VIAL | zoledronic acid | M05BA | Parenteral/Solution | blank | Within Guidelines |
| 02369257 | AFINITOR - 2.5 MG/TABLET | everolimus | L04AA | Oral Solid/Tablet | blank | Within Guidelines |
| 02339501 | AFINITOR - 5 MG/TABLET | everolimus | L04AA | Oral Solid/Tablet | blank | Within Guidelines |
| 02339528 | AFINITOR - 10 MG/TABLET | everolimus | L04AA | Oral Solid/Tablet | blank | Within Guidelines |
| 02425645 | AFINITOR DISPERZ - 2 MG/TABLET | everolimus | L04AA | Oral Solid/Tablet | blank | Within Guidelines |
| 02425653 | AFINITOR DISPERZ - 3 MG/TABLET | everolimus | L04AA | Oral Solid/Tablet | blank | Within Guidelines |
| 02425661 | AFINITOR DISPERZ - 5 MG/TABLET | everolimus | L04AA | Oral Solid/Tablet | blank | Within Guidelines |
| 02479613 | AIMOVIG - 70 MG/MILLILITER | erenumab | N02CX | Parenteral/Solution | blank | VCU |
| 02487306 | AIMOVIG - 140 MG/MILLILITER | erenumab | N02CX | Parenteral/Solution | blank | VCU |
| 02498685 | ATECTURA BREEZHALER 150/80 MG/CAPSULE | indacaterol acetate/mometasone furoate | R03AK | Pulmonary/Powder | Introduced | Under Review |
| 02498707 | ATECTURA BREEZHALER 150/160 MG/CAPSULE | indacaterol acetate/mometasone furoate | R03AK | Pulmonary/Powder | Introduced | Under Review |
| 02498693 | ATECTURA BREEZHALER 150/320 MG/CAPSULE | indacaterol acetate/mometasone furoate | R03AK | Pulmonary/Powder | Introduced | Under Review |
| 02331624 | AZARGA 1/0.5 | brinzolamide/timolol maleate | S01ED | Ophthalmic/Suspension | blank | Subj. Investigation |
| 02238873 | AZOPT - 10 MG/MILLILITER | brinzolamide | S01EC | Ophthalmic/Suspension | blank | Within Guidelines |
| 02496976 | BEOVU - 6 MG/SYRINGE | brolucizumab | S01LA | Parenteral/Solution | Introduced | Does Not Trigger |
| 02252716 | CIPRODEX 3/1 MG/MILLILITER | ciprofloxacin hydrochloride/dexamethasone | S02CA | Otic/Suspension | blank | Within Guidelines |
| 02438070 | COSENTYX - 150 MG/MILLILITER | secukinumab | L04AC | Parenteral/Solution | blank | Within Guidelines |
| 02278251 | DUO TRAV PQ 0.04/5 MG/MILLILITER | travoprost/timolol maleate | S01ED | Ophthalmic/Liquid | blank | Subj. Investigation |
| 02501244 | ENERZAIR BREEZHALER 150/50/160 MCG/CAPSULE | indacaterol acetate/glycopyrronium bromide/mometasone furoate | R03AL | Pulmonary/Powder | Introduced | Under Review |
| 02446928 | ENTRESTO 24.3/25.7 MG/TABLET | sacubitril/valsartan | C09DX | Oral Solid/Tablet | blank | Within Guidelines |
| 02446936 | ENTRESTO 48.6/51.4 MG/TABLET | sacubitril/valsartan | C09DX | Oral Solid/Tablet | blank | Within Guidelines |
| 02446944 | ENTRESTO 97.2/102.8 MG/TABLET | sacubitril/valsartan | C09DX | Oral Solid/Tablet | blank | Within Guidelines |
| 02287420 | EXJADE - 125 MG/TABLET | deferasirox | V03AC | Oral Solid/Tablet | blank | Within Guidelines |
| 02287439 | EXJADE - 250 MG/TABLET | deferasirox | V03AC | Oral Solid/Tablet | blank | Within Guidelines |
| 02287447 | EXJADE - 500 MG/TABLET | deferasirox | V03AC | Oral Solid/Tablet | blank | Within Guidelines |
| 02337819 | EXTAVIA - 0.3 MG/VIAL | interferon beta-1b | L03AB | Parenteral/Powder for solution | blank | Within Guidelines |
| 02482533 | GILENYA - 0.25 MG/CAPSULE | fingolimod hydrochloride | L04AA | Oral Solid/Capsule | blank | Within Guidelines |
| 02365480 | GILENYA - 0.5 MG/CAPSULE | fingolimod hydrochloride | L04AA | Oral Solid/Capsule | blank | Within Guidelines |
| 02253275 | GLEEVEC - 100 MG/TABLET | imatinib mesylate | L01XX | Oral Solid/Tablet | blank | Within Guidelines |
| 02253283 | GLEEVEC - 400 MG/TABLET | imatinib mesylate | L01XX | Oral Solid/Tablet | blank | Within Guidelines |
| 02460351 | ILARIS - 150 MG/MILLILITER | canakinumab | L04AC | Parenteral/Solution | blank | Within Guidelines |
| 02411393 | ILEVRO - 3 MG/MILLILITER | nepafenac | S01BC | Ophthalmic/Suspension | blank | Within Guidelines |
| 02457997 | IZBA - 0.03 MG/MILLILITER | travoprost | S01EE | Ophthalmic/Liquid | blank | Within Guidelines |
| 02452219 | JADENU - 90 MG/TABLET | deferasirox | V03AC | Oral Solid/Tablet | blank | Within Guidelines |
| 02452227 | JADENU - 180 MG/TABLET | deferasirox | V03AC | Oral Solid/Tablet | blank | Within Guidelines |
| 02452235 | JADENU - 360 MG/TABLET | deferasirox | V03AC | Oral Solid/Tablet | blank | Within Guidelines |
| 02388006 | JAKAVI - 5 MG/TABLET | ruxolitinib | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02434814 | JAKAVI - 10 MG/TABLET | ruxolitinib | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02388014 | JAKAVI - 15 MG/TABLET | ruxolitinib | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02388022 | JAKAVI - 20 MG/TABLET | ruxolitinib | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02473569 | KISQALI - 200 MG/TABLET | ribociclib | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02480514 | KYMRIAH | tisagenlecleucel | blank | Parenteral/Other | blank | Within Guidelines |
| 02496429 | MAYZENT - 0.25 MG/TABLET | siponimod | L04AA | Oral Solid/Tablet | Introduced | Within Guidelines |
| 02496437 | MAYZENT - 2 MG/TABLET | siponimod | L04AA | Oral Solid/Tablet | Introduced | Within Guidelines |
| 02409623 | MEKINIST - 0.5 MG/TABLET | trametinib | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02409658 | MEKINIST - 2 MG/TABLET | trametinib | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02264560 | MYFORTIC - 180 MG/TABLET | mycophenolate sodium | L04AA | Oral Solid/Tablet | blank | Within Guidelines |
| 02264579 | MYFORTIC - 360 MG/TABLET | mycophenolate sodium | L04AA | Oral Solid/Tablet | blank | Within Guidelines |
| 02308983 | NEVANAC - 1 MG/MILLILITER | nepafenac | S01BC | Ophthalmic/Suspension | blank | Within Guidelines |
| 02376938 | ONBREZ BREEZHALER - 75 MCG/CAPSULE | indacaterol maleate | R03AC | Pulmonary/Powder | blank | Within Guidelines |
| 02362171 | PATADAY - 2 MG/MILLILITER | olopatadine hydrochloride | S01GX | Ophthalmic/Liquid | blank | Subj. Investigation |
| 02233143 | PATANOL - 1 MG/MILLILITER | olopatadine hydrochloride | S01GX | Ophthalmic/Liquid | blank | Subj. Investigation |
| 02458551 | PAZEO - 7 MG/MILLILITER | olopatadine hydrochloride | S01GX | Ophthalmic/Liquid | blank | Within Guidelines |
| 02497069 | PIQRAY - 150 MG/TABLET | alpelisib | L01XX | Oral Solid/Tablet | Introduced | Under Review |
| 02497077 | PIQRAY - 200 MG/TABLET | alpelisib | L01XX | Oral Solid/Tablet | Introduced | Under Review |
| 02497085 | PIQRAY 50/200 MG/TABLET | alpelisib | L01XX | Oral Solid/Tablet | Introduced | Under Review |
| 02361825 | REVOLADE - 25 MG/TABLET | eltrombopag olamine | B02BX | Oral Solid/Tablet | blank | Within Guidelines |
| 02361833 | REVOLADE - 50 MG/TABLET | eltrombopag olamine | B02BX | Oral Solid/Tablet | blank | Within Guidelines |
| 02466236 | RYDAPT - 25 MG/CAPSULE | midostaurin | L01XE | Oral Solid/Capsule | blank | Within Guidelines |
| 00839191 | SANDOSTATIN - 0.05 MG/MILLILITER | octreotide | H01CB | Parenteral/Solution | blank | Within Guidelines |
| 00839205 | SANDOSTATIN - 0.1 MG/MILLILITER | octreotide | H01CB | Parenteral/Solution | blank | Within Guidelines |
| 02049392 | SANDOSTATIN - 0.2 MG/MILLILITER | octreotide | H01CB | Parenteral/Solution | blank | Within Guidelines |
| 02239323 | SANDOSTATIN LAR - 10 MG/VIAL | octreotide | H01CB | Parenteral/Modified release injections | blank | Within Guidelines |
| 02239324 | SANDOSTATIN LAR - 20 MG/VIAL | octreotide | H01CB | Parenteral/Modified release injections | blank | Within Guidelines |
| 02239325 | SANDOSTATIN LAR - 30 MG/VIAL | octreotide | H01CB | Parenteral/Modified release injections | blank | Within Guidelines |
| 02394936 | SEEBRI BREEZHALER - 50 MCG/CAPSULE | glycopyrronium bromide | R03BB | Pulmonary/Powder | blank | Within Guidelines |
| 02435411 | SIMBRINZA | brinzolamide/brimonidine tartrate | S01EC | Ophthalmic/Suspension | blank | Within Guidelines |
| 02305933 | STALEVO 50/12.5/200 MG/TABLET | levodopa/carbidopa/entacapone | N04BA | Oral Solid/Tablet | Expired | Within Guidelines |
| 02337827 | STALEVO 75/18.75/200 MG/TABLET | levodopa/carbidopa/entacapone | N04BA | Oral Solid/Tablet | Expired | Within Guidelines |
| 02305941 | STALEVO 100/25/200 MG/TABLET | levodopa/carbidopa/entacapone | N04BA | Oral Solid/Tablet | Expired | Within Guidelines |
| 02337835 | STALEVO 125/31.25/200 MG/TABLET | levodopa/carbidopa/entacapone | N04BA | Oral Solid/Tablet | Expired | Within Guidelines |
| 02305968 | STALEVO 150/37.5/200 MG/TABLET | levodopa/carbidopa/entacapone | N04BA | Oral Solid/Tablet | Expired | Within Guidelines |
| 02409607 | TAFINLAR - 50 MG/CAPSULE | dabrafenib | L01XE | Oral Solid/Capsule | blank | Within Guidelines |
| 02409615 | TAFINLAR - 75 MG/CAPSULE | dabrafenib | L01XE | Oral Solid/Capsule | blank | Within Guidelines |
| 02368250 | TASIGNA - 150 MG/CAPSULE | nilotinib hydrochloride monohydrate | L01XE | Oral Solid/Capsule | blank | Within Guidelines |
| 02315874 | TASIGNA - 200 MG/CAPSULE | nilotinib hydrochloride monohydrate | L01XE | Oral Solid/Capsule | blank | Within Guidelines |
| 02318008 | TRAVATAN Z - 0.04 MG/MILLILITER | travoprost | S01EE | Ophthalmic/Liquid | blank | Within Guidelines |
| 02368676 | TRIESENCE - 40 MG/MILLILITER | triamcinolone acetonide | S01BA | Ophthalmic/Other | blank | Within Guidelines |
| 02244673 | TRILEPTAL - 60 MG/MILLILITER | oxcarbazepine | N03AF | Oral Liquid/Suspension | Expired | Within Guidelines |
| 02242068 | TRILEPTAL - 300 MG/TABLET | oxcarbazepine | N03AF | Oral Solid/Tablet | Expired | Within Guidelines |
| 02242069 | TRILEPTAL - 600 MG/TABLET | oxcarbazepine | N03AF | Oral Solid/Tablet | Expired | Within Guidelines |
| 02326442 | TYKERB - 250 MG/TABLET | lapatinib ditosylate monohydrate | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02418282 | ULTIBRO BREEZHALER 110/50 MCG/CAPSULE | indacaterol maleate/glycopyrronium bromide | R03AL | Pulmonary/Powder | blank | Subj. Investigation |
| 02352303 | VOTRIENT - 200 MG/TABLET | pazopanib hydrochloride | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02471027 | XIIDRA - 50 MG/MILLILITER | lifitegrast | S01XA | Ophthalmic/Solution | blank | Subj. Investigation |
| 02459787 | XOLAIR - 75 MG/SYRINGE | omalizumab | R03DX | Parenteral/Solution | blank | Within Guidelines |
| 02459795 | XOLAIR - 150 MG/SYRINGE | omalizumab | R03DX | Parenteral/Solution | blank | Within Guidelines |
| 02260565 | XOLAIR - 150 MG/VIAL | omalizumab | R03DX | Parenteral/Powder for solution | blank | Within Guidelines |
| 02509695 | ZOLGENSMA | onasemnogene abeparvovec | M09AX | Parenteral/Kit | Introduced | Under Review |
| 02248296 | ZOMETA - 4 MG/VIAL | zoledronic acid | M05BA | Parenteral/Solution | Expired | Subj. Investigation |
| 02436779 | ZYKADIA - 150 MG/CAPSULE | ceritinib | L01XE | Oral Solid/Capsule | blank | Does Not Trigger |
Novo Nordisk Canada Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02417103 | NIASTASE RT - 1 MG/VIAL | eptacog alfa (activated) | B02BD | Parenteral/Powder for solution | Expired | Within Guidelines |
| 02417111 | NIASTASE RT - 2 MG/VIAL | eptacog alfa (activated) | B02BD | Parenteral/Powder for solution | Expired | Within Guidelines |
| 02417138 | NIASTASE RT - 5 MG/VIAL | eptacog alfa (activated) | B02BD | Parenteral/Powder for solution | Expired | Within Guidelines |
| 02471469 | OZEMPIC - 1 MG/DOSE | semaglutide | A10BJ | Parenteral/Solution | Expired | Within Guidelines |
| 02471477 | OZEMPIC | semaglutide | A10BJ | Parenteral/Solution | Expired | Within Guidelines |
| 02470187 | REBINYN | coagulation factor ix (recombinant), pegylated | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02470268 | REBINYN | coagulation factor ix (recombinant), pegylated | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02470276 | REBINYN | coagulation factor ix (recombinant), pegylated | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02437899 | SAXENDA - 6 MG/MILLILITER | liraglutide | A10BJ | Parenteral/Solution | Expired | Within Guidelines |
| 02389975 | TRETTEN - 15 MG/VIAL | catridecacog | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02351064 | VICTOZA - 6 MG/MILLILITER | liraglutide | A10BJ | Parenteral/Solution | Expired | Within Guidelines |
| 02474875 | XULTOPHY - 100 UNIT/MILLILITER | insulin degludec/liraglutide | A10AE | Parenteral/Solution | Expired | Within Guidelines |
| 02435187 | ZONOVATE | turoctocog alfa | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02435195 | ZONOVATE | turoctocog alfa | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02435209 | ZONOVATE | turoctocog alfa | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02435225 | ZONOVATE | turoctocog alfa | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02435233 | ZONOVATE | turoctocog alfa | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
O
Octapharma Canada Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02432951 | NUWIQ - 250 IU/VIAL | antihemophilic factor (recombinant, b-domain deleted) | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02432978 | NUWIQ - 500 IU/VIAL | antihemophilic factor (recombinant, b-domain deleted) | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02432986 | NUWIQ - 1000 IU/VIAL | antihemophilic factor (recombinant, b-domain deleted) | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02432994 | NUWIQ - 2000 IU/VIAL | antihemophilic factor (recombinant, b-domain deleted) | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02474050 | NUWIQ - 3000 IU/VIAL | antihemophilic factor (recombinant, b-domain deleted) | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02474069 | NUWIQ - 4000 IU/VIAL | antihemophilic factor (recombinant, b-domain deleted) | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
Otsuka Canada Pharmaceutical Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02322374 | ABILIFY - 2 MG/TABLET | aripiprazole | N05AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02322382 | ABILIFY - 5 MG/TABLET | aripiprazole | N05AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02322390 | ABILIFY - 10 MG/TABLET | aripiprazole | N05AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02322404 | ABILIFY - 15 MG/TABLET | aripiprazole | N05AX | Oral Solid/Tablet | blank | Does Not Trigger |
| 02322412 | ABILIFY - 20 MG/TABLET | aripiprazole | N05AX | Oral Solid/Tablet | blank | Does Not Trigger |
| 02322455 | ABILIFY - 30 MG/TABLET | aripiprazole | N05AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02420864 | ABILIFY MAINTENA - 300 MG/VIAL | aripiprazole | N05AX | Parenteral/Suspensions or Emulsions | blank | Within Guidelines |
| 02420872 | ABILIFY MAINTENA - 400 MG/VIAL | aripiprazole | N05AX | Parenteral/Suspensions or Emulsions | blank | Within Guidelines |
| 02461749 | REXULTI - 0.25 MG/TABLET | brexpiprazole | N05AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02461757 | REXULTI - 0.5 MG/TABLET | brexpiprazole | N05AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02461765 | REXULTI - 1 MG/TABLET | brexpiprazole | N05AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02461773 | REXULTI - 2 MG/TABLET | brexpiprazole | N05AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02461781 | REXULTI - 3 MG/TABLET | brexpiprazole | N05AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02461803 | REXULTI - 4 MG/TABLET | brexpiprazole | N05AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02471574 | VELPHORO - 500 MG/TABLET | sucroferric oxyhydroxide | V03AE | Oral Solid/Tablet (chewable) | blank | Does Not Trigger |
| 02481359 | VELTASSA - 8.4 G/SACHET | patiromer sorbitex calcium | V03AE | Parenteral/Powder for suspension | Introduced | Under Review |
| 02481367 | VELTASSA - 16.8 G/SACHET | patiromer sorbitex calcium | V03AE | Parenteral/Powder for suspension | blank | Subj. Investigation |
P
Paladin Labs Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02242980 | ANTIZOL - 1 G/MILLILITER | fomepizole | V03AB | Parenteral/Solution | blank | Subj. Investigation |
| 02485877 | ENVARSUS PA - 0.75 MG/TABLET | tacrolimus | L04AD | Oral Solid/Modified release tablets | blank | Does Not Trigger |
| 02485885 | ENVARSUS PA - 1 MG/TABLET | tacrolimus | L04AD | Oral Solid/Modified release tablets | blank | Does Not Trigger |
| 02485893 | ENVARSUS PA - 4 MG/TABLET | tacrolimus | L04AD | Oral Solid/Modified release tablets | blank | Does Not Trigger |
| 02257084 | FROVA - 2.5 MG/TABLET | frovatriptan succinate | N02CC | Oral Solid/Tablet | Expired | Subj. Investigation |
| 02437333 | ICLUSIG - 15 MG/TABLET | ponatinib hydrochloride | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02247698 | METADOL - 1 MG/TABLET | methadone hydrochloride | N07BC | Oral Solid/Tablet | blank | Within Guidelines |
| 02247699 | METADOL - 5 MG/TABLET | methadone hydrochloride | N07BC | Oral Solid/Tablet | blank | Within Guidelines |
| 02247700 | METADOL - 10 MG/TABLET | methadone hydrochloride | N07BC | Oral Solid/Tablet | blank | Within Guidelines |
| 02247701 | METADOL - 25 MG/TABLET | methadone hydrochloride | N07BC | Oral Solid/Tablet | blank | Within Guidelines |
| 02459132 | MOVAPO - 10 MG/MILLILITER | apomorphine hydrochloride | N04BC | Parenteral/Solution | blank | Does Not Trigger |
| 02415577 | NUCYNTA EXTENDED RELEASE - 50 MG/TABLET | tapentadol hydrochloride | N02AX | Oral Solid/Modified release tablets | blank | Does Not Trigger |
| 02415585 | NUCYNTA EXTENDED RELEASE - 100 MG/TABLET | tapentadol hydrochloride | N02AX | Oral Solid/Modified release tablets | blank | Does Not Trigger |
| 02415593 | NUCYNTA EXTENDED RELEASE - 150 MG/TABLET | tapentadol hydrochloride | N02AX | Oral Solid/Modified release tablets | blank | Does Not Trigger |
| 02415607 | NUCYNTA EXTENDED RELEASE - 200 MG/TABLET | tapentadol hydrochloride | N02AX | Oral Solid/Modified release tablets | blank | Does Not Trigger |
| 02415615 | NUCYNTA EXTENDED RELEASE - 250 MG/TABLET | tapentadol hydrochloride | N02AX | Oral Solid/Modified release tablets | blank | Does Not Trigger |
| 02378272 | NUCYNTA IR - 50 MG/TABLET | tapentadol hydrochloride | N02AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02378280 | NUCYNTA IR - 75 MG/TABLET | tapentadol hydrochloride | N02AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02378299 | NUCYNTA IR - 100 MG/TABLET | tapentadol hydrochloride | N02AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02398257 | SILENOR - 3 MG/TABLET | doxepin | N06AA | Oral Solid/Tablet | blank | Does Not Trigger |
| 02398265 | SILENOR - 6 MG/TABLET | doxepin | N06AA | Oral Solid/Tablet | blank | Does Not Trigger |
| 02411849 | VEREGEN - 100 MG/GRAM | sinecatechins | D06BB | Topical/Ointment | blank | Does Not Trigger |
| blank | WAKIX - 5 MG/TABLET | pitolisant | N07XX | Oral Solid/Tablet | blank | Under Review |
| blank | WAKIX - 20 MG/TABLET | pitolisant | N07XX | Oral Solid/Tablet | blank | Under Review |
| 02388316 | XIAFLEX - 0.9 MG/VIAL | collagenase clostridium histolyticum | M09AB | Parenteral/Powder for solution | blank | Within Guidelines |
Partner Therapeutics, Inc
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| blank | LEUKINE - 250 MCG/MILLILITER | sargramostim | L03AA | Parenteral/Solution | blank | Subj. Investigation |
Pediapharm Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02459655 | OTIXAL 3/0.25 MG/MILLILITER | ciprofloxacin/flucinolone acetonide | S02CA | Otic/Solution | blank | Within Guidelines |
Pfizer Canada Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02232043 | ARICEPT - 5 MG/TABLET | donepezil hydrochloride | N06DA | Oral Solid/Tablet | blank | Within Guidelines |
| 02232044 | ARICEPT - 10 MG/TABLET | donepezil hydrochloride | N06DA | Oral Solid/Tablet | blank | Within Guidelines |
| 02269457 | ARICEPT RDT - 5 MG/TABLET | donepezil hydrochloride | N06DA | Oral Solid/Tablet | blank | Does Not Trigger |
| 02269465 | ARICEPT RDT - 10 MG/TABLET | donepezil hydrochloride | N06DA | Oral Solid/Tablet | blank | Does Not Trigger |
| 02242705 | AROMASIN - 25 MG/TABLET | exemestane | L02BG | Oral Solid/Tablet | blank | Within Guidelines |
| 02293773 | BENEFIX - 500 UNIT/VIAL | coagulation factor ix (recombinant) | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02293781 | BENEFIX - 1000 UNIT/VIAL | coagulation factor ix (recombinant) | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02293803 | BENEFIX - 2000 UNIT/VIAL | coagulation factor ix (recombinant) | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02392984 | BENEFIX - 3000 UNIT/VIAL | coagulation factor ix (recombinant) | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02473909 | BESPONSA - 0.9 MG/VIAL | inotuzumab ozogamicin | L01XC | Parenteral/Powder for solution | blank | Subj. Investigation |
| 02419149 | BOSULIF - 100 MG/TABLET | bosutinib | L01XE | Oral Solid/Tablet | blank | Subj. Investigation |
| 02419157 | BOSULIF - 500 MG/TABLET | bosutinib | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02291177 | CHAMPIX - 0.5 MG/TABLET | varenicline tartrate | N07BA | Oral Solid/Tablet | blank | Does Not Trigger |
| 02291185 | CHAMPIX - 1 MG/TABLET | varenicline tartrate | N07BA | Oral Solid/Tablet | blank | Within Guidelines |
| 02298309 | CHAMPIX | varenicline tartrate | N07BA | Oral Solid/Tablet | blank | Within Guidelines |
| 02425637 | ELELYSO - 200 IU/VIAL | taliglucerase alpha | A16AB | Parenteral/Solution | blank | Within Guidelines |
| 02330695 | ERAXIS (WITHOUT SOLVENT) - 100 MG/VIAL | anidulafungin | J02AX | Parenteral/Powder for solution | Expired | Does Not Trigger |
| 02476991 | EUCRISA - 20 MG/GRAM | crisaborole | D11AX | Topical/Ointment | blank | Within Guidelines |
| 02401762 | GENOTROPIN - 0.6 MG/SYRINGE | somatropin | H01AC | Parenteral/Powder for solution | blank | Does Not Trigger |
| 02401770 | GENOTROPIN - 0.8 MG/SYRINGE | somatropin | H01AC | Parenteral/Powder for solution | blank | Within Guidelines |
| 02401789 | GENOTROPIN - 1 MG/SYRINGE | somatropin | H01AC | Parenteral/Powder for solution | blank | Within Guidelines |
| 02401797 | GENOTROPIN - 1.2 MG/SYRINGE | somatropin | H01AC | Parenteral/Powder for solution | blank | Within Guidelines |
| 02401800 | GENOTROPIN - 1.4 MG/SYRINGE | somatropin | H01AC | Parenteral/Powder for solution | blank | Subj. Investigation |
| 02401819 | GENOTROPIN - 1.6 MG/SYRINGE | somatropin | H01AC | Parenteral/Powder for solution | blank | Does Not Trigger |
| 02401827 | GENOTROPIN - 1.8 MG/SYRINGE | somatropin | H01AC | Parenteral/Powder for solution | blank | Within Guidelines |
| 02401835 | GENOTROPIN - 2 MG/SYRINGE | somatropin | H01AC | Parenteral/Powder for solution | blank | Within Guidelines |
| 02401703 | GENOTROPIN - 5.3 MG/PEN | somatropin | H01AC | Parenteral/Powder for solution | blank | Within Guidelines |
| 02401711 | GENOTROPIN - 12 MG/PEN | somatropin | H01AC | Parenteral/Powder for solution | blank | Within Guidelines |
| 02401746 | GENOTROPIN MINIQUICK - 0.2 MG/SYRINGE | somatropin | H01AC | Parenteral/Powder for solution | Introduced | Under Review |
| 02401754 | GENOTROPIN MINIQUICK - 0.4 MG/SYRINGE | somatropin | H01AC | Parenteral/Powder for solution | Introduced | Under Review |
| 02453150 | IBRANCE - 75 MG/CAPSULE | palbociclib | L01XE | Oral Solid/Capsule | blank | Subj. Investigation |
| 02453169 | IBRANCE - 100 MG/CAPSULE | palbociclib | L01XE | Oral Solid/Capsule | blank | Within Guidelines |
| 02453177 | IBRANCE - 125 MG/CAPSULE | palbociclib | L01XE | Oral Solid/Capsule | blank | Within Guidelines |
| 02493535 | IBRANCE - 75 MG/TABLET | palbociclib | L01XE | Oral Solid/Tablet | Introduced | Under Review |
| 02493543 | IBRANCE - 100 MG/TABLET | palbociclib | L01XE | Oral Solid/Tablet | Introduced | Under Review |
| 02493551 | IBRANCE - 125 MG/TABLET | palbociclib | L01XE | Oral Solid/Tablet | Introduced | Under Review |
| 02389630 | INLYTA - 1 MG/TABLET | axitinib | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02389649 | INLYTA - 5 MG/TABLET | axitinib | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02485966 | LORBRENA - 25 MG/TABLET | lorlatinib | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02485974 | LORBRENA - 100 MG/TABLET | lorlatinib | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02402904 | NIMENRIX - 5 MCG/DOSE | meningococcal polysaccharide groups a, c, w-135 and y conjugate vaccine | J07AH | Parenteral/Powder for solution | blank | Within Guidelines |
| 02437147 | PRECEDEX - 4 MCG/MILLILITER | dexmedetomidine hydrochloride | N05CM | Parenteral/Solution | blank | Within Guidelines |
| 02339366 | PRECEDEX - 100 MCG/MILLILITER | dexmedetomidine hydrochloride | N05CM | Parenteral/Solution | blank | Subj. Investigation |
| 02335204 | PREVNAR 13 - 0.5 ML/SYRINGE | pneumococcal 13-valent conjugate vaccine | J07AL | Parenteral/Suspensions or Emulsions | blank | Within Guidelines |
| 02321092 | PRISTIQ - 50 MG/TABLET | desvenlafaxine succinate | N06AX | Oral Solid/Modified release tablets | blank | Subj. Investigation |
| 02321106 | PRISTIQ - 100 MG/TABLET | desvenlafaxine succinate | N06AX | Oral Solid/Modified release tablets | blank | Subj. Investigation |
| 02243237 | RAPAMUNE - 1 MG/MILLILITER | sirolimus | L04AA | Oral Liquid/Solution | blank | Does Not Trigger |
| 02247111 | RAPAMUNE - 1 MG/TABLET | sirolimus | L04AA | Oral Solid/Tablet | blank | Subj. Investigation |
| 02272199 | SOMAVERT - 10 MG/VIAL | pegvisomant | H01AX | Parenteral/Powder for solution | blank | Within Guidelines |
| 02272202 | SOMAVERT - 15 MG/VIAL | pegvisomant | H01AX | Parenteral/Powder for solution | blank | Within Guidelines |
| 02272210 | SOMAVERT - 20 MG/VIAL | pegvisomant | H01AX | Parenteral/Powder for solution | blank | Within Guidelines |
| 02448831 | SOMAVERT - 25 MG/VIAL | pegvisomant | H01AX | Parenteral/Powder for solution | blank | Within Guidelines |
| 02448858 | SOMAVERT - 30 MG/VIAL | pegvisomant | H01AX | Parenteral/Powder for solution | blank | Within Guidelines |
| 02280795 | SUTENT - 12.5 MG/CAPSULE | sunitinib malate | L01XE | Oral Solid/Capsule | blank | Within Guidelines |
| 02280809 | SUTENT - 25 MG/CAPSULE | sunitinib malate | L01XE | Oral Solid/Capsule | blank | Within Guidelines |
| 02280817 | SUTENT - 50 MG/CAPSULE | sunitinib malate | L01XE | Oral Solid/Capsule | blank | Within Guidelines |
| 02304104 | TORISEL - 25 MG/VIAL | temsirolimus | L01XE | Parenteral/Solution | blank | Does Not Trigger |
| 02380021 | TOVIAZ - 4 MG/TABLET | fesoterodine fumarate | G04BD | Oral Solid/Modified release tablets | blank | Within Guidelines |
| 02380048 | TOVIAZ - 8 MG/TABLET | fesoterodine fumarate | G04BD | Oral Solid/Modified release tablets | blank | Within Guidelines |
| 02468751 | TRUMENBA 60/60 | neisseria meningitidis group b recombinant lipoprotein 2086 subfamily a/neisseria meningitidis group b recombinant lipoprotein 2088 subfamily b | J07AH | Parenteral/Suspensions or Emulsions | blank | Does Not Trigger |
| 02285401 | TYGACIL - 50 MG/VIAL | tigecycline | J01AA | Parenteral/Powder for solution | blank | Does Not Trigger |
| 02486024 | VIZIMPRO - 15 MG/TABLET | dacomitinib | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02486040 | VIZIMPRO - 45 MG/TABLET | dacomitinib | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02495732 | VYNDAQEL - 20 MG/CAPSULE | tafamidis meglumine | N07XX | Oral Solid/Capsule | Introduced/Expired | Within Guidelines |
| 02384256 | XALKORI - 200 MG/CAPSULE | crizotinib | L01XE | Oral Solid/Capsule | blank | Does Not Trigger |
| 02384264 | XALKORI - 250 MG/CAPSULE | crizotinib | L01XE | Oral Solid/Capsule | blank | Within Guidelines |
| 02423898 | XELJANZ - 5 MG/TABLET | tofacitinib | L04AA | Oral Solid/Tablet | blank | Within Guidelines |
| 02480786 | XELJANZ - 10 MG/TABLET | tofacitinib | L04AA | Oral Solid/Tablet | blank | Within Guidelines |
| 02470608 | XELJANZ XR - 11 MG/TABLET | tofacitinib | L04AA | Oral Solid/Modified release tablets | blank | Subj. Investigation |
| 02309483 | XYNTHA - 250 UNIT/VIAL | moroctocog alfa | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02309491 | XYNTHA - 500 UNIT/VIAL | moroctocog alfa | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02374064 | XYNTHA SOLOFUSE - 500 UNIT/SYRINGE | moroctocog alfa | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02374072 | XYNTHA SOLOFUSE - 1000 UNIT/SYRINGE | moroctocog alfa | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02374080 | XYNTHA SOLOFUSE - 2000 UNIT/SYRINGE | moroctocog alfa | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02374099 | XYNTHA SOLOFUSE - 3000 UNIT/SYRINGE | moroctocog alfa | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02223716 | ZITHROMAX - 20 MG/MILLILITER | azithromycin | J01FA | Oral Liquid/Powder for suspension | blank | Does Not Trigger |
| 02223724 | ZITHROMAX - 40 MG/MILLILITER | azithromycin | J01FA | Oral Liquid/Powder for suspension | blank | Subj. Investigation |
| 02212021 | ZITHROMAX - 250 MG/TABLET | azithromycin | J01FA | Oral Solid/Tablet | blank | Within Guidelines |
| 02239952 | ZITHROMAX IV - 500 MG/VIAL | azithromycin | J01FA | Parenteral/Powder for solution | blank | Within Guidelines |
| 02243685 | ZYVOXAM - 2 MG/MILLILITER | linezolid | J01XX | Parenteral/Solution | blank | Subj. Investigation |
| 02243686 | ZYVOXAM - 20 MG/MILLILITER | linezolid | J01XX | Oral Liquid/Powder for suspension | blank | Does Not Trigger |
| 02243684 | ZYVOXAM - 600 MG/TABLET | linezolid | J01XX | Oral Solid/Tablet | blank | Does Not Trigger |
Pharmascience Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02406772 | CYTARABINE - 100 MG/MILLILITER | cytarabine | L01BC | Parenteral/Solution | Expired | Subj. Investigation |
Pierre Fabre Dermo-Cosmétique Canada Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02457857 | HEMANGIOL - 3.75 MG/MILLILITER | propranolol hydrochloride | C07AA | Oral Liquid/Solution | blank | Within Guidelines |
PTC Therapeutics International Limited
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| blank | TRANSLARNA - 125 MG/POUCH | ataluren | M09AX | Oral Solid/Effervescent granules | blank | Does Not Trigger |
| blank | TRANSLARNA - 250 MG/POUCH | ataluren | M09AX | Oral Solid/Effervescent granules | blank | Does Not Trigger |
Purdue Pharma
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02231934 | OXY-IR - 5 MG/TABLET | oxycodone hydrochloride | N02AA | Oral Solid/Tablet | blank | Does Not Trigger |
| 02240131 | OXY-IR - 10 MG/TABLET | oxycodone hydrochloride | N02AA | Oral Solid/Tablet | blank | Does Not Trigger |
| 02240132 | OXY-IR - 20 MG/TABLET | oxycodone hydrochloride | N02AA | Oral Solid/Tablet | blank | Within Guidelines |
| 02372525 | OXYNEO - 10 MG/TABLET | oxycodone hydrochloride | N02AA | Oral Solid/Modified release tablets | blank | Within Guidelines |
| 02372533 | OXYNEO - 15 MG/TABLET | oxycodone hydrochloride | N02AA | Oral Solid/Modified release tablets | blank | Within Guidelines |
| 02372797 | OXYNEO - 20 MG/TABLET | oxycodone hydrochloride | N02AA | Oral Solid/Modified release tablets | blank | Within Guidelines |
| 02372541 | OXYNEO - 30 MG/TABLET | oxycodone hydrochloride | N02AA | Oral Solid/Modified release tablets | blank | Within Guidelines |
| 02372568 | OXYNEO - 40 MG/TABLET | oxycodone hydrochloride | N02AA | Oral Solid/Modified release tablets | blank | Within Guidelines |
| 02372576 | OXYNEO - 60 MG/TABLET | oxycodone hydrochloride | N02AA | Oral Solid/Modified release tablets | blank | Within Guidelines |
| 02372584 | OXYNEO - 80 MG/TABLET | oxycodone hydrochloride | N02AA | Oral Solid/Modified release tablets | blank | Within Guidelines |
| 02387425 | TARGIN 5/2.5 MG/TABLET | oxycodone hydrochloride/naloxone hydrochloride | N02AA | Oral Solid/Modified release tablets | blank | Does Not Trigger |
| 02339609 | TARGIN 10/5 MG/TABLET | oxycodone hydrochloride/naloxone hydrochloride | N02AA | Oral Solid/Modified release tablets | blank | Does Not Trigger |
| 02339617 | TARGIN 20/10 MG.TABLET | oxycodone hydrochloride/naloxone hydrochloride | N02AA | Oral Solid/Modified release tablets | blank | Within Guidelines |
| 02339625 | TARGIN 40/20 MG/TABLET | oxycodone hydrochloride/naloxone hydrochloride | N02AA | Oral Solid/Modified release tablets | blank | Within Guidelines |
R
Recordati Rare Diseases
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| blank | LEDAGA - 160 MCG/GRAM | chlormethine hydrochloride | L01AA | Topical/Gel | blank | Under Review |
| 02413299 | SIGNIFOR - 0.3 MG/MILLILITER | pasireotide | H01CB | Parenteral/Solution | blank | Within Guidelines |
| 02413302 | SIGNIFOR - 0.6 MG/MILLILITER | pasireotide | H01CB | Parenteral/Solution | blank | Within Guidelines |
| 02480425 | SIGNIFOR LAR - 10 MG/VIAL | pasireotide | H01CB | Parenteral/Powder for suspension | blank | Does Not Trigger |
| 02437252 | SIGNIFOR LAR - 20 MG/VIAL | pasireotide | H01CB | Parenteral/Powder for solution | blank | Within Guidelines |
| 02437260 | SIGNIFOR LAR - 40 MG/VIAL | pasireotide | H01CB | Parenteral/Powder for solution | blank | Within Guidelines |
| 02437279 | SIGNIFOR LAR - 60 MG/VIAL | pasireotide | H01CB | Parenteral/Powder for solution | blank | Within Guidelines |
S
Sandoz Canada Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02246533 | ANGIOMAX - 250 MG/VIAL | bivalirudin | B01AE | Parenteral/Powder for solution | blank | Within Guidelines |
Sanofi Genzyme, A Division of Sanofi-Aventis Canada Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02463261 | CERDELGA - 84 MG/CAPSULE | eliglustat | A16AX | Oral Solid/Capsule | blank | Subj. Investigation |
Sanofi Pasteur Limited
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02279924 | MENACTRA | meningococcal polysaccharide diphtheria toxoid conjugate vaccine | J07AH | Parenteral/Solution | blank | Within Guidelines |
Sanofi-Aventis Canada Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02464276 | ADLYXINE - 0.05 MG/MILLILITER | lixisenatide | A10BJ | Parenteral/Solution | blank | Does Not Trigger |
| 02464284 | ADLYXINE - 0.1 MG/MILLILITER | lixisenatide | A10BJ | Parenteral/Solution | blank | Does Not Trigger |
| 02254506 | ALDURAZYME - 0.58 MG/MILLILITER | laronidase | A16AB | Parenteral/Solution | Expired | Within Guidelines |
| 02279460 | APIDRA - 100 UNIT/MILLILITER | insulin glulisine | A10AB | Parenteral/Solution | blank | Within Guidelines |
| 02279479 | APIDRA - 100 UNIT/MILLILITER | insulin glulisine | A10AB | Parenteral/Solution | blank | Within Guidelines |
| 02294346 | APIDRA SOLOSTAR - 100 UNIT/MILLILITER | insulin glulisine | A10AB | Parenteral/Solution | blank | Within Guidelines |
| 02241888 | ARAVA - 10 MG/TABLET | leflunomide | L04AA | Oral Solid/Tablet | Expired | Within Guidelines |
| 02241889 | ARAVA - 20 MG/TABLET | leflunomide | L04AA | Oral Solid/Tablet | Expired | Within Guidelines |
| 02378582 | CAPRELSA - 100 MG/TABLET | vandetanib | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02378590 | CAPRELSA - 300 MG/TABLET | vandetanib | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02330407 | CLOLAR - 20 MG/VIAL | clofarabine | L01BB | Parenteral/Solution | blank | Does Not Trigger |
| 02492504 | DUPIXENT - 200 MG/SYRINGE | dupilumab | D11AH | Parenteral/Solution | blank | Within Guidelines |
| 02470365 | DUPIXENT - 300 MG/SYRINGE | dupilumab | D11AH | Parenteral/Solution | blank | Within Guidelines |
| 02460521 | KEVZARA - 150 MG/SYRINGE | sarilumab | L04AC | Parenteral/Solution | blank | Within Guidelines |
| 02472961 | KEVZARA - 150 MG/PEN | sarilumab | L04AC | Parenteral/Solution | blank | Within Guidelines |
| 02460548 | KEVZARA - 200 MG/SYRINGE | sarilumab | L04AC | Parenteral/Solution | blank | Within Guidelines |
| 02472988 | KEVZARA - 200 MG/PEN | sarilumab | L04AC | Parenteral/Solution | blank | Within Guidelines |
| 02245689 | LANTUS - 100 UNIT/MILLILITER | insulin glargine | A10AE | Parenteral/Solution | blank | Within Guidelines |
| 02251930 | LANTUS - 100 UNIT/MILLILITER | insulin glargine | A10AE | Parenteral/Solution | blank | Subj. Investigation |
| 02294338 | LANTUS SOLOSTAR - 100 UNIT/MILLILITER | insulin glargine | A10AE | Parenteral/Solution | blank | Within Guidelines |
| 02377225 | MOZOBIL - 20 MG/MILLILITER | plerixafor | L03AX | Parenteral/Solution | blank | Within Guidelines |
| 02284863 | MYOZYME - 50 MG/VIAL | alglucosidase alfa | A16AB | Parenteral/Powder for solution | blank | Within Guidelines |
| 02453819 | PRALUENT - 75 MG/MILLILITER | alirocumab | C10AX | Parenteral/Solution | blank | Within Guidelines |
| 02453835 | PRALUENT - 150 MG/MILLILITER | alirocumab | C10AX | Parenteral/Solution | blank | Within Guidelines |
| 02498235 | SARCLISA - 100 MG/VIAL | isatuximab | L01XC | Parenteral/Solution | Introduced | Under Review |
| 02498243 | SARCLISA - 500 MG/VIAL | isatuximab | L01XC | Parenteral/Solution | Introduced | Under Review |
| 02478293 | SOLIQUA - 3 ML/PEN | insuline glargine/lixisenatide | A10AE | Parenteral/Solution | blank | Does Not Trigger |
| 02493373 | TOUJEO DOUBLESTAR - 300 UNIT/MILLILITER | insulin glargine | A10AE | Parenteral/Solution | Introduced | Within Guidelines |
| 02441829 | TOUJEO SOLOSTAR - 300 UNIT/MILLILITER | insulin glargine | A10AE | Parenteral/Solution | blank | Within Guidelines |
Santen SAS
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02484137 | VERKAZIA - 1 MG/MILLILITER | cyclosporine | S01XA | Ophthalmic/Other | blank | Subj. Investigation |
Searchlight Pharma Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02273217 | ENABLEX - 7.5 MG/TABLET | darifenacin | G04BD | Oral Solid/Tablet | blank | Within Guidelines |
| 02273225 | ENABLEX - 15 MG/TABLET | darifenacin | G04BD | Oral Solid/Tablet | blank | Within Guidelines |
Seagan Canada
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02401347 | ADCETRIS - 50 MG/VIAL | brentuximab vedotin | L01XC | Parenteral/Powder for solution | blank | Within Guidelines |
| 02499827 | TUKYSA - 50 MG/TABLET | tucatinib | L01EH | Oral Solid/Tablet | Introduced | Under Review |
| 02499835 | TUKYSA - 150 MG/TABLET | tucatinib | L01EH | Oral Solid/Tablet | Introduced | Under Review |
Seqirus Canada Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02362384 | FLUAD - 45 MCG/DOSE | influenza vaccine, surface antigen, inactivated | J07BB | Parenteral/Suspensions or Emulsions | blank | Subj. Investigation |
| 02434881 | FLUAD PEDIATRIC - 22.5 MCG/DOSE | influenza vaccine, surface antigen, inactivated | J07BB | Parenteral/Suspensions or Emulsions | blank | Within Guidelines |
Servier Canada Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| blank | BELEODAQ - 500 MG/VIAL | belinostat | L01XX | Parenteral/Powder for solution | blank | Within Guidelines |
| 02356422 | DIAMICRON MR - 60 MG/TABLET | gliclazide | A10BB | Oral Solid/Modified release tablets | blank | Within Guidelines |
| 02481820 | FOLOTYN - 20 MG/MILLILITER | pralatrexate | L01BA | Parenteral/Solution | blank | Within Guidelines |
| 02459973 | LANCORA - 5 MG/TABLET | ivabradine | C01EB | Oral Solid/Tablet | blank | Within Guidelines |
| 02459981 | LANCORA - 7.5 MG/TABLET | ivabradine | C01EB | Oral Solid/Tablet | blank | Within Guidelines |
| 02458640 | LIXIANA - 15 MG/TABLET | edoxaban | B01AF | Oral Solid/Tablet | blank | Within Guidelines |
| 02458659 | LIXIANA - 30 MG/TABLET | edoxaban | B01AF | Oral Solid/Tablet | blank | Within Guidelines |
| 02458667 | LIXIANA - 60 MG/TABLET | edoxaban | B01AF | Oral Solid/Tablet | blank | Within Guidelines |
| 02467135 | ONIVYDE - 4.3 MG/MILLILITER | irinotecan hydrochloride trihydrate | L01XX | Parenteral/Suspensions or Emulsions | blank | Within Guidelines |
| 02451530 | VIACORAM 3.5/2.5 MG/TABLET | perindopril arginine/amlodipine besylate | C09BB | Oral Solid/Tablet | blank | Within Guidelines |
| 02451549 | VIACORAM 7/5 MG/TABLET | perindopril arginine/amlodipine besylate | C09BB | Oral Solid/Tablet | blank | Within Guidelines |
| 02451557 | VIACORAM 14/10 MG/TABLET | perindopril arginine/amlodipine besylate | C09BB | Oral Solid/Tablet | blank | Within Guidelines |
Sprout Pharmaceuticals, Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 2473550 | ADDYI - 100 MG/TABLET | flibanserin | G02CX | Oral Solid/Tablet | Expired | Within Guidelines |
Sterimax Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02130181 | PROLEUKIN - 22000000 UNIT/VIAL | aldesleukin | L03AC | Parenteral/Powder for solution | blank | Within Guidelines |
Sun Pharmaceutical Industries, Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| blank | ILUMYA - 100 MG/MILLILITER | tildrakizumab | L04AC | Parenteral/Solution | blank | Under Review |
| 02500337 | ODOMZO - 200 MG/CAPSULE | sonidegibe | L01XX | Oral Solid/Capsule | blank | Under Review |
Sunovion Pharmaceuticals Canada Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02426862 | APTIOM - 200 MG/TABLET | eslicarbazepine acetate | N03AF | Oral Solid/Tablet | blank | Within Guidelines |
| 02426870 | APTIOM - 400 MG/TABLET | eslicarbazepine acetate | N03AF | Oral Solid/Tablet | blank | Within Guidelines |
| 02426889 | APTIOM - 600 MG/TABLET | eslicarbazepine acetate | N03AF | Oral Solid/Tablet | blank | Within Guidelines |
| 02426897 | APTIOM - 800 MG/TABLET | eslicarbazepine acetate | N03AF | Oral Solid/Tablet | blank | Within Guidelines |
| 02465493 | CUBICIN RF - 500 MG/VIAL | daptomycin | J01XX | Parenteral/Powder for solution | blank | Within Guidelines |
| 02500264 | KYNMOBI - 10 MG/FILM | apomorphine hydrochloride | N04BC | Oral Solid/Film (soluble) | Introduced | Within Guidelines |
| 02500272 | KYNMOBI - 15 MG/FILM | apomorphine hydrochloride | N04BC | Oral Solid/Film (soluble) | Introduced | Within Guidelines |
| 02500280 | KYNMOBI - 20 MG/FILM | apomorphine hydrochloride | N04BC | Oral Solid/Film (soluble) | Introduced | Within Guidelines |
| 02500299 | KYNMOBI - 25 MG/FILM | apomorphine hydrochloride | N04BC | Oral Solid/Film (soluble) | Introduced | Within Guidelines |
| 02500302 | KYNMOBI - 30 MG/FILM | apomorphine hydrochloride | N04BC | Oral Solid/Film (soluble) | Introduced | Within Guidelines |
| 02422050 | LATUDA - 20 MG/TABLET | lurasidone hydrochloride | N05AE | Oral Solid/Tablet | blank | Within Guidelines |
| 02387751 | LATUDA - 40 MG/TABLET | lurasidone hydrochloride | N05AE | Oral Solid/Tablet | blank | Within Guidelines |
| 02413361 | LATUDA - 60 MG/TABLET | lurasidone hydrochloride | N05AE | Oral Solid/Tablet | blank | Within Guidelines |
| 02387778 | LATUDA - 80 MG/TABLET | lurasidone hydrochloride | N05AE | Oral Solid/Tablet | blank | Within Guidelines |
| 02387786 | LATUDA - 120 MG/TABLET | lurasidone hydrochloride | N05AE | Oral Solid/Tablet | blank | Within Guidelines |
Swedish Orphan Biovitrum, SOBI AB
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02245913 | KINERET - 100 MG/SYRINGE | anakinra | L04AA | Parenteral/Solution | blank | Within Guidelines |
| blank | GAMIFANT - 10 MG/VIAL | emapalumab | L04AA | Parenteral/Solution | blank | Subj. Investigation |
| 02469693 | ORFADIN - 4 MG/MILLILITER | nitisinone | A16AX | Oral Liquid/Suspension | blank | Under Review |
| 02459698 | ORFADIN - 2 MG/CAPSULE | nitisinone | A16AX | Oral Solid/Capsule | blank | Subj. Investigation |
| 02459701 | ORFADIN - 5 MG/CAPSULE | nitisinone | A16AX | Oral Solid/Capsule | blank | Subj. Investigation |
| 02459728 | ORFADIN - 10 MG/CAPSULE | nitisinone | A16AX | Oral Solid/Capsule | blank | Subj. Investigation |
| 02459736 | ORFADIN - 20 MG/CAPSULE | nitisinone | A16AX | Oral Solid/Capsule | blank | Under Review |
T
Taiho Pharma Canada
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02501600 | INQOVI 35/100 MG/TABLET | decitabine/cedazuridine | L01BC | Oral Solid/Tablet | Introduced | Under Review |
| 02472104 | LONSURF 15/6.14 MG/TABLET | trifluridine/tipiracil | L01BC | Oral Solid/Tablet | blank | Subj. Investigation |
| 02472112 | LONSURF 20/8.19 MG/TABLET | trifluridine/tipiracil | L01BC | Oral Solid/Tablet | blank | Within Guidelines |
Takeda Canada Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02248808 | ADDERALL XR - 5 MG/CAPSULE | mixed salts amphetamine | N06BA | Oral Solid/Modified release capsules | blank | Within Guidelines |
| 02248809 | ADDERALL XR - 10 MG/CAPSULE | mixed salts amphetamine | N06BA | Oral Solid/Modified release capsules | blank | Within Guidelines |
| 02248810 | ADDERALL XR - 15 MG/CAPSULE | mixed salts amphetamine | N06BA | Oral Solid/Modified release capsules | blank | Within Guidelines |
| 02248811 | ADDERALL XR - 20 MG/CAPSULE | mixed salts amphetamine | N06BA | Oral Solid/Modified release capsules | blank | Within Guidelines |
| 02248812 | ADDERALL XR - 25 MG/CAPSULE | mixed salts amphetamine | N06BA | Oral Solid/Modified release capsules | blank | Within Guidelines |
| 02248813 | ADDERALL XR - 30 MG/CAPSULE | mixed salts amphetamine | N06BA | Oral Solid/Modified release capsules | blank | Within Guidelines |
| 02459035 | ADYNOVATE - 250 IU/VIAL | antihemophilic factor (recombinant), pegylated | B02BD | Parenteral/Powder for solution | blank | Under Review |
| 02459043 | ADYNOVATE - 500 IU/VIAL | antihemophilic factor (recombinant), pegylated | B02BD | Parenteral/Powder for solution | blank | Under Review |
| 02459051 | ADYNOVATE - 1000 IU/VIAL | antihemophilic factor (recombinant), pegylated | B02BD | Parenteral/Powder for solution | blank | Under Review |
| 02459078 | ADYNOVATE - 2000 IU/VIAL | antihemophilic factor (recombinant), pegylated | B02BD | Parenteral/Powder for solution | blank | Under Review |
| 02498626 | ADYNOVATE - 3000 IU/VIAL | antihemophilic factor (recombinant), pegylated | B02BD | Parenteral/Powder for solution | Introduced | Under Review |
| 02479214 | ALUNBRIG - 90 MG/TABLET | brigatinib | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02479222 | ALUNBRIG - 180 MG/TABLET | brigatinib | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02479230 | ALUNBRIG 90/180 MG/PACK | brigatinib | L01XE | Oral Solid/Tablet | blank | Within Guidelines |
| 02354950 | DEXILANT - 30 MG/CAPSULE | dexlansoprazole | A02BC | Oral Solid/Capsule | blank | Subj. Investigation |
| 02354969 | DEXILANT - 60 MG/CAPSULE | dexlansoprazole | A02BC | Oral Solid/Capsule | blank | Subj. Investigation |
| 02497875 | ENTYVIO - 108 MG/SYRINGE | vedolizumab | L04AA | Parenteral/Powder for solution | Introduced | Under Review |
| 02497867 | ENTYVIO - 108 MG/PEN | vedolizumab | L04AA | Parenteral/Solution | Introduced | Under Review |
| 02436841 | ENTYVIO - 300 MG/VIAL | vedolizumab | L04AA | Parenteral/Powder for solution | blank | Within Guidelines |
| 02287145 | FOSRENOL - 250 MG/TABLET | lanthanum carbonate hydrate | V03AE | Oral Solid/Tablet | blank | Does Not Trigger |
| 02287153 | FOSRENOL - 500 MG/TABLET | lanthanum carbonate hydrate | V03AE | Oral Solid/Tablet | blank | Within Guidelines |
| 02287161 | FOSRENOL - 750 MG/TABLET | lanthanum carbonate hydrate | V03AE | Oral Solid/Tablet | blank | Within Guidelines |
| 02287188 | FOSRENOL - 1000 MG/TABLET | lanthanum carbonate hydrate | V03AE | Oral Solid/Tablet | blank | Within Guidelines |
| 02206021 | IMMUNINE VH | factor ix coagulation | B02BD | Parenteral/Powder for solution | blank | Within Guidelines |
| 02409100 | INTUNIV XR - 1 MG/TABLET | guanfacine hydrochloride | C02AC | Oral Solid/Modified release tablets | blank | Within Guidelines |
| 02409119 | INTUNIV XR - 2 MG/TABLET | guanfacine hydrochloride | C02AC | Oral Solid/Modified release tablets | blank | Within Guidelines |
| 02409127 | INTUNIV XR - 3 MG/TABLET | guanfacine hydrochloride | C02AC | Oral Solid/Modified release tablets | blank | Within Guidelines |
| 02409135 | INTUNIV XR - 4 MG/TABLET | guanfacine hydrochloride | C02AC | Oral Solid/Modified release tablets | blank | Within Guidelines |
| 02417219 | KAZANO 12.5/500 MG/TABLET | alogliptin benzoate/metformin hydrochloride | A10BD | Oral Solid/Tablet | blank | Within Guidelines |
| 02417227 | KAZANO 12.5/850 MG/TABLET | alogliptin benzoate/metformin hydrochloride | A10BD | Oral Solid/Tablet | blank | Does Not Trigger |
| 02417235 | KAZANO 12.5/1000 MG/TABLET | alogliptin benzoate/metformin hydrochloride | A10BD | Oral Solid/Tablet | blank | Within Guidelines |
| 02297558 | MEZAVANT - 1.2 G/TABLET | mesalazine | A07EC | Oral Solid/Modified release tablets | Expired | Within Guidelines |
| 02417189 | NESINA - 6.25 MG/TABLET | alogliptin benzoate | A10BH | Oral Solid/Tablet | blank | Within Guidelines |
| 02417197 | NESINA - 12.5 MG/TABLET | alogliptin benzoate | A10BH | Oral Solid/Tablet | blank | Within Guidelines |
| 02417200 | NESINA - 25 MG/TABLET | alogliptin benzoate | A10BH | Oral Solid/Tablet | blank | Within Guidelines |
| 02456796 | NINLARO - 2.3 MG/CAPSULE | ixazomib citrate | L01XX | Oral Solid/Capsule | blank | Within Guidelines |
| 02456818 | NINLARO - 3 MG/CAPSULE | ixazomib citrate | L01XX | Oral Solid/Capsule | blank | Within Guidelines |
| 02456826 | NINLARO - 4 MG/CAPSULE | ixazomib citrate | L01XX | Oral Solid/Capsule | blank | Within Guidelines |
| 02447401 | OBIZUR - 500 UNIT/MILLILITER | antihemophilic factor (recombinant), porcine sequence | B02BD | Parenteral/Powder for solution | blank | Subj. Investigation |
| 02389983 | ONDISSOLVE ODF - 4 MG/FILM | ondansetron | A04AA | Oral Solid/Film (soluble) | blank | Subj. Investigation |
| 02389991 | ONDISSOLVE ODF - 8 MG/FILM | ondansetron | A04AA | Oral Solid/Film (soluble) | blank | Subj. Investigation |
| 02241804 | PANTOLOC - 20 MG/TABLET | pantoprazole sodium | A02BC | Oral Solid/Tablet | blank | Does Not Trigger |
| 02229453 | PANTOLOC - 40 MG/TABLET | pantoprazole sodium | A02BC | Oral Solid/Tablet | blank | Within Guidelines |
| 02249057 | REPLAGAL - 250 IU/VIAL | agalsidase alfa | A16AB | Parenteral/Solution | blank | Within Guidelines |
| 02445727 | REVESTIVE - 5 MG/VIAL | teduglutide | A16AX | Oral Liquid/Powder for solution | blank | Within Guidelines |
| 02431939 | RIXUBIS - 500 UNIT/VIAL | nonacog gamma | B02BD | Parenteral/Powder for solution | blank | Does Not Trigger |
| 02431947 | RIXUBIS - 1000 UNIT/VIAL | nonacog gamma | B02BD | Parenteral/Powder for solution | blank | Does Not Trigger |
| 02431955 | RIXUBIS - 2000 UNIT/VIAL | nonacog gamma | B02BD | Parenteral/Powder for solution | blank | Subj. Investigation |
| 02431963 | RIXUBIS - 3000 UNIT/VIAL | nonacog gamma | B02BD | Parenteral/Powder for solution | blank | Subj. Investigation |
| 02480948 | TAKHZYRO - 150 MG/MILLILITER | lanadelumab | B06AC | Parenteral/Solution | blank | Subj. Investigation |
| 02267233 | TECTA - 40 MG/TABLET | pantoprazole magnesium | A02BC | Oral Solid/Tablet | blank | Within Guidelines |
| 02357380 | ULORIC - 80 MG/TABLET | febuxostat | M04AA | Oral Solid/Tablet | blank | Within Guidelines |
| 02357119 | VPRIV - 400 UNIT/VIAL | velaglucerase alfa | A16AB | Parenteral/Powder for solution | blank | Within Guidelines |
| 02490226 | VYVANSE - 10 MG/TABLET | lisdexamfetamine dimesylate | N06BA | Oral Solid/Tablet (chewable) | blank | Subj. Investigation |
| 02490234 | VYVANSE - 20 MG/TABLET | lisdexamfetamine dimesylate | N06BA | Oral Solid/Tablet (chewable) | blank | Subj. Investigation |
| 02490242 | VYVANSE - 30 MG/TABLET | lisdexamfetamine dimesylate | N06BA | Oral Solid/Tablet (chewable) | blank | Subj. Investigation |
| 02490250 | VYVANSE - 40 MG/TABLET | lisdexamfetamine dimesylate | N06BA | Oral Solid/Tablet (chewable) | blank | Subj. Investigation |
| 02490269 | VYVANSE - 50 MG/TABLET | lisdexamfetamine dimesylate | N06BA | Oral Solid/Tablet (chewable) | blank | Subj. Investigation |
| 02490277 | VYVANSE - 60 MG/TABLET | lisdexamfetamine dimesylate | N06BA | Oral Solid/Tablet (chewable) | blank | Subj. Investigation |
| 02439603 | VYVANSE - 10 MG/CAPSULE | lisdexamfetamine dimesylate | N06BA | Oral Solid/Capsule | blank | Within Guidelines |
| 02347156 | VYVANSE - 20 MG/CAPSULE | lisdexamfetamine dimesylate | N06BA | Oral Solid/Capsule | blank | Within Guidelines |
| 02322951 | VYVANSE - 30 MG/CAPSULE | lisdexamfetamine dimesylate | N06BA | Oral Solid/Capsule | blank | Within Guidelines |
| 02347164 | VYVANSE - 40 MG/CAPSULE | lisdexamfetamine dimesylate | N06BA | Oral Solid/Capsule | blank | Within Guidelines |
| 02322978 | VYVANSE - 50 MG/CAPSULE | lisdexamfetamine dimesylate | N06BA | Oral Solid/Capsule | blank | Within Guidelines |
| 02347172 | VYVANSE - 60 MG/CAPSULE | lisdexamfetamine dimesylate | N06BA | Oral Solid/Capsule | blank | Within Guidelines |
| 02458071 | VYVANSE - 70 MG/CAPSULE | lisdexamfetamine dimesylate | N06BA | Oral Solid/Capsule | blank | Subj. Investigation |
Teva Canada Innovation G.P.-S.E.N.C.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02467895 | AERMONY RESPICLICK - 55 MCG/ACTUATION | fluticasone propionate | R03BA | Pulmonary/Powder (metered dose) | Introduced | Within Guidelines |
| 02467909 | AERMONY RESPICLICK - 113 MCG/ACTUATION | fluticasone propionate | R03BA | Pulmonary/Powder (metered dose) | Introduced | Within Guidelines |
| 02467917 | AERMONY RESPICLICK - 232 MCG/ACTUATION | fluticasone propionate | R03BA | Pulmonary/Powder (metered dose) | Introduced | Within Guidelines |
| 02497859 | AJOVY - 225 MG/SYRINGE | fremanezumab | N02CD | Parenteral/Solution | Introduced | Under Review |
| 02245619 | COPAXONE - 20 MG/SYRINGE | glatiramer acetate | L03AX | Parenteral/Solution | blank | Within Guidelines |
| 02456915 | COPAXONE - 40 MG/MILLILITER | glatiramer acetate | L03AX | Parenteral/Solution | blank | Within Guidelines |
| 02408007 | FENTORA - 100 MCG/TABLET | fentanyl citrate | N02AB | Dental - Sublingual Buccal/Sublingual tablets | blank | Does Not Trigger |
| 02408015 | FENTORA - 200 MCG/TABLET | fentanyl citrate | N02AB | Dental - Sublingual Buccal/Sublingual tablets | blank | Does Not Trigger |
| 02408023 | FENTORA - 400 MCG/TABLET | fentanyl citrate | N02AB | Dental - Sublingual Buccal/Sublingual tablets | blank | Within Guidelines |
| 02408031 | FENTORA - 600 MCG/TABLET | fentanyl citrate | N02AB | Dental - Sublingual Buccal/Sublingual tablets | blank | Does Not Trigger |
| 02408058 | FENTORA - 800 MCG/TABLET | fentanyl citrate | N02AB | Dental - Sublingual Buccal/Sublingual tablets | blank | Does Not Trigger |
| 02346176 | SEASONIQUE 0.15/0.03-0.01 | levonorgestrel/ethinyl estradiol + ethinyl estradiol | G03AA | Oral Solid/Tablet | blank | Does Not Trigger |
Thrombogenics N.V.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02410818 | JETREA - 2.5 MG/MILLILITER | ocriplasmin | S01XA | Ophthalmic/Other | blank | Within Guidelines |
U
UCB Canada Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02452987 | BRIVLERA - 10 MG/MILLILITER | brivaracetam | N03AX | Oral Liquid/Solution | Introduced | Within Guidelines |
| 02452995 | BRIVLERA - 10 MG/MILLILITER | brivaracetam | N03AX | Parenteral/Solution | blank | Within Guidelines |
| 02452936 | BRIVLERA - 10 MG/TABLET | brivaracetam | N03AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02452944 | BRIVLERA - 25 MG/TABLET | brivaracetam | N03AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02452952 | BRIVLERA - 50 MG/TABLET | brivaracetam | N03AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02452960 | BRIVLERA - 75 MG/TABLET | brivaracetam | N03AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02452979 | BRIVLERA - 100 MG/TABLET | brivaracetam | N03AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02331675 | CIMZIA - 200 MG/MILLILITER | certolizumab pegol | L04AB | Parenteral/Powder for solution | blank | Within Guidelines |
| 02465574 | CIMZIA - 200 MG/MILLILITER | certolizumab pegol | L04AB | Parenteral/Powder for solution | blank | Within Guidelines |
| 02403897 | NEUPRO - 1 MG/PATCH | rotigotine | N04BC | Topical/Patches | blank | Within Guidelines |
| 02403900 | NEUPRO - 2 MG/PATCH | rotigotine | N04BC | Topical/Patches | blank | Within Guidelines |
| 02403919 | NEUPRO - 3 MG/PATCH | rotigotine | N04BC | Topical/Patches | blank | Within Guidelines |
| 02403927 | NEUPRO - 4 MG/PATCH | rotigotine | N04BC | Topical/Patches | blank | Within Guidelines |
| 02403935 | NEUPRO - 6 MG/PATCH | rotigotine | N04BC | Topical/Patches | blank | Within Guidelines |
| 02403943 | NEUPRO - 8 MG/PATCH | rotigotine | N04BC | Topical/Patches | blank | Within Guidelines |
| 02357666 | VIMPAT - 10 MG/MILLILITER | lacosamide | N03AX | Parenteral/Solution | blank | Within Guidelines |
| 02357615 | VIMPAT - 50 MG/TABLET | lacosamide | N03AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02357623 | VIMPAT - 100 MG/TABLET | lacosamide | N03AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02357631 | VIMPAT - 150 MG/TABLET | lacosamide | N03AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02357658 | VIMPAT - 200 MG/TABLET | lacosamide | N03AX | Oral Solid/Tablet | blank | Within Guidelines |
Ultragenyx Pharmaceuticals Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02483629 | CRYSVITA - 10 MG/MILLILITER | burosumab | M05BX | Parenteral/Solution | blank | Within Guidelines |
| 02483637 | CRYSVITA - 20 MG/MILLILITER | burosumab | M05BX | Parenteral/Solution | blank | Subj. Investigation |
| 02483645 | CRYSVITA - 30 MG/MILLILITER | burosumab | M05BX | Parenteral/Solution | blank | Subj. Investigation |
UPJOHN Canada ULC
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02273233 | CADUET 5/10 MG/TABLET | amlodipine besylate/atorvastatin calcium | C10BX | Oral Solid/Tablet | Expired | Does Not Trigger |
| 02273241 | CADUET 5/20 MG/TABLET | amlodipine besylate/atorvastatin calcium | C10BX | Oral Solid/Tablet | Expired | Within Guidelines |
| 02273268 | CADUET 5/40 MG/TABLET | amlodipine besylate/atorvastatin calcium | C10BX | Oral Solid/Tablet | Expired | Within Guidelines |
| 02273276 | CADUET 5/80 MG/TABLET | amlodipine besylate/atorvastatin calcium | C10BX | Oral Solid/Tablet | Expired | Does Not Trigger |
| 02273284 | CADUET 10/10 MG/TABLET | amlodipine besylate/atorvastatin calcium | C10BX | Oral Solid/Tablet | Expired | Within Guidelines |
| 02273292 | CADUET 10/20 MG/TABLET | amlodipine besylate/atorvastatin calcium | C10BX | Oral Solid/Tablet | Expired | Does Not Trigger |
| 02273306 | CADUET 10/40 MG/TABLET | amlodipine besylate/atorvastatin calcium | C10BX | Oral Solid/Tablet | Expired | Within Guidelines |
| 02273314 | CADUET 10/80 MG/TABLET | amlodipine besylate/atorvastatin calcium | C10BX | Oral Solid/Tablet | Expired | Within Guidelines |
| 02239941 | CELEBREX - 100 MG/CAPSULE | celecoxib | M01AH | Oral Solid/Capsule | Expired | Within Guidelines |
| 02239942 | CELEBREX - 200 MG/CAPSULE | celecoxib | M01AH | Oral Solid/Capsule | Expired | Within Guidelines |
| 02239064 | DETROL - 1 MG/TABLET | tolterodine tartrate | G04BD | Oral Solid/Tablet | blank | Within Guidelines |
| 02239065 | DETROL - 2 MG/TABLET | tolterodine tartrate | G04BD | Oral Solid/Tablet | blank | Within Guidelines |
| 02244612 | DETROL LA - 2 MG/CAPSULE | tolterodine l-tartrate | G04BD | Oral Solid/Modified release capsules | blank | Within Guidelines |
| 02244613 | DETROL LA - 4 MG/CAPSULE | tolterodine l-tartrate | G04BD | Oral Solid/Modified release capsules | blank | Within Guidelines |
| 02230711 | LIPITOR - 10 MG/TABLET | atorvastatin calcium | C10AA | Oral Solid/Tablet | Expired | Within Guidelines |
| 02230713 | LIPITOR - 20 MG/TABLET | atorvastatin calcium | C10AA | Oral Solid/Tablet | Expired | Within Guidelines |
| 02230714 | LIPITOR - 40 MG/TABLET | atorvastatin calcium | C10AA | Oral Solid/Tablet | Expired | Within Guidelines |
| 02243097 | LIPITOR - 80 MG/TABLET | atorvastatin calcium | C10AA | Oral Solid/Tablet | Expired | Within Guidelines |
| 02268418 | LYRICA - 25 MG/CAPSULE | pregabalin | N03AX | Oral Solid/Capsule | Expired | Within Guidelines |
| 02268426 | LYRICA - 50 MG/CAPSULE | pregabalin | N03AX | Oral Solid/Capsule | Expired | Within Guidelines |
| 02268434 | LYRICA - 75 MG/CAPSULE | pregabalin | N03AX | Oral Solid/Capsule | Expired | Within Guidelines |
| 02268450 | LYRICA - 150 MG/CAPSULE | pregabalin | N03AX | Oral Solid/Capsule | Expired | Within Guidelines |
| 02268477 | LYRICA - 225 MG/CAPSULE | pregabalin | N03AX | Oral Solid/Capsule | Expired | Within Guidelines |
| 02268485 | LYRICA - 300 MG/CAPSULE | pregabalin | N03AX | Oral Solid/Capsule | Expired | Within Guidelines |
| 02279401 | REVATIO - 20 MG/TABLET | sildenafil citrate | G04BE | Oral Solid/Tablet | Expired | Subj. Investigation |
| 02341611 | REVATIO IV - 0.8 MG/MILLILITER | sildenafil citrate | G04BE | Parenteral/Solution | Expired | Does Not Trigger |
| 02239766 | VIAGRA - 25 MG/TABLET | sildenafil citrate | G04BE | Oral Solid/Tablet | Expired | Within Guidelines |
| 02239767 | VIAGRA - 50 MG/TABLET | sildenafil citrate | G04BE | Oral Solid/Tablet | Expired | Within Guidelines |
| 02239768 | VIAGRA - 100 MG/TABLET | sildenafil citrate | G04BE | Oral Solid/Tablet | Expired | Within Guidelines |
| 02298597 | ZELDOX - 20 MG/CAPSULE | ziprasidone hydrochloride monohydrate | N05AE | Oral Solid/Capsule | Expired | Within Guidelines |
| 02298600 | ZELDOX - 40 MG/CAPSULE | ziprasidone hydrochloride monohydrate | N05AE | Oral Solid/Capsule | Expired | Within Guidelines |
| 02298619 | ZELDOX - 60 MG/CAPSULE | ziprasidone hydrochloride monohydrate | N05AE | Oral Solid/Capsule | Expired | Within Guidelines |
| 02298627 | ZELDOX - 80 MG/CAPSULE | ziprasidone hydrochloride monohydrate | N05AE | Oral Solid/Capsule | Expired | Within Guidelines |
| 02132702 | ZOLOFT - 25 MG/CAPSULE | sertraline hydrochloride | N06AB | Oral Solid/Capsule | Expired | Within Guidelines |
| 01962817 | ZOLOFT - 50 MG/CAPSULE | sertraline hydrochloride | N06AB | Oral Solid/Capsule | Expired | Within Guidelines |
| 01962779 | ZOLOFT - 100 MG/CAPSULE | sertraline hydrochloride | N06AB | Oral Solid/Capsule | Expired | Within Guidelines |
V
Valeo Pharma
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02484641 | ONSTRYV - 50 MG/TABLET | safinamide | N04BD | Oral Solid/Tablet | blank | Within Guidelines |
| 02484668 | ONSTRYV - 100 MG/TABLET | safinamide | N04BD | Oral Solid/Tablet | blank | Within Guidelines |
| 02351528 | YONDELIS - 1 MG/VIAL | trabectedin | L01CX | Parenteral/Powder for solution | blank | Does Not Trigger |
Verity Pharmaceuticals Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02429977 | ZEULIDE DEPOT - 3.75 MG/DOSE | leuprolide acetate | L02AE | Parenteral/Powder for solution | Expired | Subj. Investigation |
| 02462699 | ZEULIDE DEPOT - 22.5 MG/VIAL | leuprolide acetate | L02AE | Parenteral/Kit | Expired | Subj. Investigation |
Vertex Pharmaceuticals Canada Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| blank | ELEXACAFTOR/TEZACAFTOR/IVACAFTOR AND IVACAFTOR | elexacaftor/tezacaftor/ivacaftor and ivacaftor | blank | Oral Solid/Tablet | Introduced | Under Review |
| 02442612 | KALYDECO - 50 MG/PACK | ivacaftor | R07AX | Oral Solid/Effervescent granules | blank | Within Guidelines |
| 02442620 | KALYDECO - 75 MG/PACK | ivacaftor | R07AX | Oral Solid/Effervescent granules | blank | Within Guidelines |
| 02397412 | KALYDECO - 150 MG/TABLET | ivacaftor | R07AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02483831 | ORKAMBI 100/125 MG/GRANULE | lumacaftor/ivacaftor | R07AX | Oral Solid/Granules | blank | Subj. Investigation |
| 02463040 | ORKAMBI 125/100 MG/TABLET | lumacaftor/ivacaftor | R07AX | Oral Solid/Tablet | blank | Subj. Investigation |
| 02483858 | ORKAMBI 150/188 MG/GRANULE | lumacaftor/ivacaftor | R07AX | Oral Solid/Granules | blank | Subj. Investigation |
| 02451379 | ORKAMBI 200/125 MG/TABLET | lumacaftor/ivacaftor | R07AX | Oral Solid/Tablet | blank | Subj. Investigation |
| 02478080 | SYMDEKO 100/150;150 | tezacaftor/ivacaftor and ivacaftor | R07AX | Oral Solid/Tablet | blank | Within Guidelines |
VIIV Healthcare ULC
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02497220 | CABENUVA 200/300 - 1000 MG/KIT | cabotegravir/rilpivirine | J05AR | Parenteral/Kit | Introduced | Under Review |
| 02497247 | CABENUVA 200/300 - 1500 MG/KIT | cabotegravir/rilpivirine | J05AR | Parenteral/Kit | Introduced | Under Review |
| 02299844 | CELSENTRI - 150 MG/TABLET | maraviroc | J05AX | Oral Solid/Tablet | blank | Does Not Trigger |
| 02299852 | CELSENTRI - 300 MG/TABLET | maraviroc | J05AX | Oral Solid/Tablet | blank | Does Not Trigger |
| 02491753 | DOVATO 50/300 MG/TABLET | dolutegravir/lamivudine | J05AR | Oral Solid/Tablet | blank | Within Guidelines |
| 02475774 | JULUCA 50/25 MG/TABLET | dolutegravir/rilpivirine | J05AR | Oral Solid/Tablet | blank | Within Guidelines |
| 02269341 | KIVEXA 300/600 MG/TABLET | abacavir sulfate/ lamivudine | J05AF | Oral Solid/Tablet | Expired | Subj. Investigation |
| 02461218 | TIVICAY - 10 MG/TABLET | dolutegravir | J05AX | Oral Solid/Tablet | blank | Does Not Trigger |
| 02461226 | TIVICAY - 25 MG/TABLET | dolutegravir | J05AX | Oral Solid/Tablet | blank | Does Not Trigger |
| 02414945 | TIVICAY - 50 MG/TABLET | dolutegravir | J05AX | Oral Solid/Tablet | blank | Within Guidelines |
| 02430932 | TRIUMEQ 50/600/300 MG/TABLET | dolutegravir/abacavir/lamivudine | J05AR | Oral Solid/Tablet | blank | Within Guidelines |
| 02497204 | VOCABRIA - 30 MG/TABLET | cabotegravir | J05AR | Oral Solid/Tablet | Introduced | Under Review |
X
Xediton Pharmaceuticals Inc.
| DIN | Brand Name | Medicinal Ingredient | ATC | Dosage | Comments | Status |
|---|---|---|---|---|---|---|
| 02242367 | VISUDYNE - 15 MG/VIAL | verteporfin | L01XX | Parenteral/Powder for solution | blank | Within Guidelines |
* Does not include medicines introduced or patented in December 2020.
Page details
- Date modified: